8015 - jccnb
TRANSCRIPT
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³æ¬ã¬ã€ãã©ã€ã³ã«å«ãŸããã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã UPDATES
NCCNNational ComprehensiveCancer Network®
NCCN è «çåŠèšåºå®è·µã¬ã€ãã©ã€ã³â¢
ä¹³çã¹ã¯ãªãŒãã³ã°ãšèšºæ
ã¬ã€ãã©ã€ã³
2007 幎第 1 ç
ã€ã¥ã
www.nccn.org
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ã€ã¥ã
NCCN ä¹³çã¹ã¯ãªãŒãã³ã°ã»èšºæå§å¡äŒå§å¡ * Therese B. Bevers, MD/Chair Ã
The University of Texas M. D. Anderson Cancer Center
* Benjamin O. Anderson, MD ¶ Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Ermelinda Bonaccio, MD§ Roswell Park Cancer Institute
Saundra Buys, MD â â¡ Ã Huntsman Cancer Institute at the University of Utah
Mary B. Daly, MD, PhD â Fox Chase Cancer Center
Peter J. Dempsey, MD § The University of Texas M. D. Anderson Cancer Center
William B. Farrar, MD ¶ Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University
Irving Fleming, MD ¶ St. Jude Children's Research Hospital/University of Tennessee Health Sciences Center
* Judy E. Garber, MD, MPH â Dana-Farber/Partners CancerCare
Randall E. Harris, MD, PhD Ã â Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University
* Mark Helvie, MD §à University of Michigan Comprehensive Cancer Center
Susan Hoover, MD ¶ H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida
Seema A. Khan, MD â Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Helen Krontiras, MD ¶ University of Alabama at Birmingham Comprehensive Cancer Center
Sara Shaw, MD § City of Hope Cancer Center
Celette Sugg Skinner, PhD Duke Comprehensive Cancer Center
Mary Lou Smith, JD, MBA ¥ Patient Consultant
Theodore N. Tsangaris, MD ¶ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cheryl Williams, MD § UNMC Eppley Cancer Center at The Nebraska Medical Center
§ æŸå°ç·çæ³ã»æŸå°ç·è «çåŠ Â¶ å€ç§åŠã»è «çå€ç§åŠ â è «çå ç§åŠ â¡ è¡æ¶²åŠã»è «çè¡æ¶²åŠ à å°åå»çãšäºé²ç®¡çãå«ãå ç§åŠ â ç çåŠ Â¥ æ£è æ¯æŽå£äœ * ææžå§å¡äŒå§å¡
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ãã®è§£èª¬ã¯ãæ°èŠã«æŽæ°ãã
ãã¢ã«ãŽãªãºã ã«å¯Ÿå¿ããã
ãæ¹èšäžã§ããã
ç® æ¬¡ NCCN ä¹³çã¹ã¯ãªãŒãã³ã°ã»èšºæå§å¡äŒå§å¡
èŠè§ŠèšºïŒBSCR-1ïŒ
éåžžãªã¹ã¯ã身äœæèŠé°æ§ïŒBSCR-1ïŒ
é«ãªã¹ã¯ã身äœæèŠé°æ§ïŒBSCR-2ïŒ
çåæ§ã身äœæèŠéœæ§ïŒBSCR-3ïŒ
ããã/è «ç€ã30 æ³ä»¥äžïŒBSCR-4ïŒ
ããã/è «ç€ã30 æ³æªæºïŒBSCR-8ïŒ
ä¹³é åæ³ã觊ç¥å¯èœãªè «ç€ãªãïŒBSCR-12ïŒ
é察称æ§é°åœ±ãŸãã¯å°çµç¯åœ¢æïŒBSCR-13ïŒ
ç®èã®å€åïŒBSCR-14ïŒ
ãã³ã¢ã°ã©ãã£è©äŸ¡ïŒBSCR-15ïŒ
ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ã®èæ ®ç¹ïŒBSCR-AïŒ
ä¿®æ£ Gail ã¢ãã«ã§çšããããå±éºå åïŒBSCR-BïŒ
ãã³ã¢ã°ã©ãã£è©äŸ¡ã«ããŽãªãŒã®å®çŸ©ïŒBSCR-CïŒ
ã¬ã€ãã©ã€ã³çŽ¢åŒ ä¹³çã¹ã¯ãªãŒãã³ã°ã»èšºæã¬ã€ãã©ã€ã³ãå°å·ãã
èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã
è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠããã
èšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCNå çæœèšã«ãããèšåºè©Šéšã®ãªã³ã©ã€ã³
æ€çŽ¢ã¯ãããã¯ãªãã¯ïŒ nccn.org/clinical_trials/physician.html NCCN ã³ã³ã»ã³ãµã¹ã«ããŽãªãŒïŒ ç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽ
ãªãŒ2A ã§ããã NCCN ã®ã³ã³ã»ã³ãµã¹åé¡ïŒç¹ã«æå®ã®ãªãé
ããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã NCCNã®ã³ã³ã»ã³ãµã¹ã«ããŽãªãŒãåç §
ã¬ã€ãã©ã€ã³ã®æŽæ°æŠèŠ
ãã®ææžã®å©çšã«é¢ãããã«ãã¯ãããã¯ãªãã¯
解 説 åèæç®
ãã®ã¬ã€ãã©ã€ã³ã¯ãçŸåšåãå ¥ããããŠããæ²»çã¢ãããŒãã«å¯ŸããèŠè§£ã«ã€ããŠãå·çè ããåæã«éããå 容ãèšãããã®ã§ããããã®ã¬ã€ãã©
ã€ã³ãé©çšãŸãã¯åç §ããããšããŠããèšåºå»ã«ã¯ãåå¥ã®èšåºç¶æ³ã«å¿ããŠå¥åã®å»åŠçå€æãäžããäžã§ãæ£è ã®ã±ã¢ãŸãã¯æ²»çæ³ã決å®ããããš
ãæåŸ ããããNational Comprehensive CancerNetwork (NCCN) ã¯ããã®å 容ã䜿çšããŸãã¯é©çšã«ã€ããŠãããªãè¡šæãä¿èšŒãè¡ããã®ã§ã¯ãªãã
ãã®é©çšãŸãã¯äœ¿çšã«ã€ããŠãããªã責任ãè² ããªãããã®ã¬ã€ãã©ã€ã³ã®èäœæš©ã¯National Comprehensive Cancer Network (NCCN) ã«ãããNCCNã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ããã«å«ãŸããã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã©2007.
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã UPDATES
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ã¬ã€ãã©ã€ã³ã®æŽæ°æŠèŠ ä¹³çã¹ã¯ãªãŒãã³ã°ã»èšºæã¬ã€ãã©ã€ã³ 2006 幎第 1 çãã 2007 幎第 1 çãžã®å€æŽäºé ã¯äžèšã®éãã§ããã ⢠匷åãªå®¶ææŽãŸãã¯éºäŒççŽ å ã25 æ³ä»¥äžã ãã³ã¢ã°ã©ã ããã³èŠè§Šèšºã®è£å©ãšããŠMRIãèããïŒå§å¡äŒã¯ãç®æ¡æž
ãé ç®ããæ¯å¹Žã®ïŒannualïŒãšããæ°éè©ãåé€ããïŒBSCR-2ïŒã ⢠ãããïŒè «ç€ 30 æ³ä»¥äžãè¶ é³æ³¢ããç å€ãç¹å®ã§ããªããããè¶ é³æ³¢
æ€æ»ã§ç°åžžãèªããããªããã«å€æŽïŒBSCR-4ïŒã ⢠远跡è©äŸ¡ãçµç¹çæ€ãŸã㯠3ïœ6 ã¶æããšã®çµé芳å¯Â±ç»å蚺æã 1ïœ2幎å®æœããŠãå®å®æ§ãè©äŸ¡ïŒã倧ããã®å¢å€§ãããèŠè§Šèšºã§é²è¡ãŸãã¯å€§
ããã®å¢å€§ãã«çœ®ãæ¿ããïŒBSCR-4ïŒã ⢠è泚oã«æŸå°ç¶ç¢çãå ããïŒBSCR-5ãBSCR-6ãBSCR-7ãBSCR-10ã
BSCR-11 ããã³ BSCR-16ïŒã ⢠çµç¹èšºæãã³ã¢éçæ€ïŒå§å¡äŒã¯ã³ã¢éçæ€ã®åŸã«ãæãŸããããè¿œå
ãããããã«ãåé€ã®åŸã«ããã³ã¢éçæ€ãã§ããªãå Žåããšããæèšã
è¿œå ããïŒBSCR-6ïŒã ⢠远跡è©äŸ¡ãè «ç€åçºãè¶ é³æ³¢ïŒè¶ é³æ³¢ã®åŸã®æšå¥šãšããŠã®ãæãŸããã
ãåé€ããïŒBSCR-7ïŒã ⢠çµç¹åŠïŒçŽ°è蚺ïŒãç·ç¶è ºè «ãããè¯æ§ãã«ããçãããæªæ§ãã«å€æŽã
ãïŒBSCR-10ïŒã ⢠çµç¹åŠïŒçŽ°è蚺ïŒæ°ããã«ããŽãªãŒãšããŠãçµç¹äžååãè¿œå ãã
ïŒBSCR-10ïŒã
⢠远跡è©äŸ¡ã3ïœ6 ã¶æããšã« 1ïœ2 幎é芳å¯ïŒã2cmæªæºã®å Žåã®ã¿ããšã
ãæ°éè©ãåé€ãããããã«ãå€ç§çåé€ã®åŸã«ãããããã倧ããã®å Ž
åããšããæ°éè©ãè¿œå ããïŒBSCR-10ïŒã ⢠乳é åæ³ã觊ç¥å¯èœãªè «ç€ãªãïŒäž¡åŽæ§ã§ä¹³æ±æ§ã®åãåé€ãã
ïŒBSCR-12ïŒã ⢠éèªçºçãå€ä¹³ç®¡æ§ã40 æ³ä»¥äžïŒãã³ã¢ã°ã©ã 蚺æïŒBSCR-15ïŒãåç §
ããªã³ã¯ãšããŠè¿œå ããïŒBSCR-12ïŒã ⢠乳é åæ³ã觊ç¥å¯èœãªè «ç€ãªãïŒæç¶çãã蚺å¯ã§åçŸæ§ãããããå
ããããšã«ãã£ãŠæ確ã«ããïŒBSCR-12ïŒã ⢠BI-RADS®ã«ããŽãªãŒ4ïœ5 ããã³ïŒãŸãã¯å å®æ§ãŸãã¯éåçŽè¿èãå€
ç§çåé€ãããè¿èå è «ç€ãå£è¥åããè¿œå ããããšã«ãã£ãŠæ確ã«ãã
ïŒBSCR-14ïŒã ⢠ç çæèŠïŒç»åãäžèŽïŒãªã¹ãããæŸå°ç¶ç¢çãåé€ïŒBSCR-16ïŒã ⢠æ°ããä¹³çã¹ã¯ãªãŒãã³ã°ã®èæ ®ç¹ã1 è©ŠéšïŒDMISTïŒãããè¥å¹Žå¥³æ§
ããã³ä¹³æ¿çµç¹ãçš å¯ãªå¥³æ§ã«ãããããžã¿ã«ãã³ã¢ã°ã©ãã£ã®æçæ§
ã瀺åããããããã®ããŒãžã«è¿œå ãããïŒBSCR-AïŒã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-1
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ã¹ã¯ãªãŒãã³ã°ãŸãã¯çç¶ã®ã«ããŽãªãŒ ã¹ã¯ãªãŒãã³ã°ã®è¿œè·¡ a
èŠè§Šèšº a
ç¡çåæ§ãã€èŠè§Šèšºé°æ§
éåžžãªã¹ã¯
20 æ³ä»¥äž 40æ³æªæº
40 æ³ä»¥äž
1ïœ3 幎ããšã®èŠè§Šèšº å®æçãªèªå·±æ€èšºãå§ãããã g
æ¯å¹Žã®èŠè§Šèšº æ¯å¹Žã®ãã³ã¢ã°ã©ã å®æçãªèªå·±æ€èšºãå§ãããã g
é«ãªã¹ã¯ïŒb èžéšãžã®æŸå°ç·æ²»çã®æ¢åŸïŒããšãã°ãã³ãã«ïŒ 浞最æ§ä¹³çã® 5 幎éã®çºçãªã¹ã¯ã35 æ³ä»¥äžã®å¥³æ§ã§ 1.7ïŒ ä»¥äž c 匷åãªå®¶ææŽ d ãŸãã¯éºäŒççŽ å e,f LCIS/ ALH(Atypical Lobular Hyperplasia) ä¹³çã®æ¢åŸæŽ
é«ãªã¹ã¯ã¹ã¯ãªãŒãã³ã°ã®è¿œè·¡ãåç §ïŒBSCR-2ïŒ
ãã³ã¢ã°ã©ãã£è©äŸ¡ãåç § ïŒBSCR-15ïŒ æèŠãåç §ïŒBSCR-3ïŒ
çåæ§ãŸãã¯èŠè§Šèšºéœæ§
a ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ã®èæ ®ç¹ãåç §ïŒBSCR-AïŒ b å®æ§çããã³å®éçè©äŸ¡ã®è©³çŽ°ã«ã€ããŠã¯NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç § c ä¿®æ£Gail ã¢ãã«ã§çšããããå±éºå åãåç §ïŒBSCR-BïŒ d 匷åãªå®¶ææŽã®å®çŸ©ã«ã€ããŠã¯NCCN éºäŒç/家ææ§ãã€ãªã¹ã¯è©äŸ¡ã¬ã€ãã©ã€ã³ãåç § e ã¢ã¡ãªã«èšåºè «çåŠäŒã® æ°æ¹é声æã«ããã æ°ã®å®çŸ©ã®ãšããïŒãçæåæ§ã«é¢ããéºäŒåæ€æ»ãJ Clin Oncol 2003, 21:2397-2406. f NCCN éºäŒç/家ææ§ãã€ãªã¹ã¯è©äŸ¡ã¬ã€ãã©ã€ã³ãåç § g 女æ§ã¯èªåã®ä¹³æ¿ã®ããšãããç¥ã£ãŠããã¹ãã§ãããå€åãèŠã€ãããå³åº§ã«äž»æ²»å»ã«å ±åããªããã°ãªããªããå®æçã«äžè²«ããèªå·±æ€èšºïŒBreast self-exam: BSEïŒãè¡ã£
ãŠãããšãèªåã®ä¹³æ¿ã®ããšãããåããããã«ãªããéçµåã®å¥³æ§ã®å Žåã¯BSE ãçççµäºæã«è¡ãã®ã ãæçã§ããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-2
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ã¹ã¯ãªãŒãã³ã°ãŸãã¯çç¶ã®ã«ããŽãªãŒ ã¹ã¯ãªãŒãã³ã°ã®è¿œè·¡ é«ãªã¹ã¯ïŒ
èžéšãžã®æŸå°ç·çæ³ã®æ¢åŸ
25 æ³æªæº
25 æ³ä»¥äž
æ¯å¹Žã®èŠè§Šèšº å®æçãªèªå·±æ€èšºãå§ãããã g
æ¯å¹Žã®ãã³ã¢ã°ã©ã ïŒ6ïœ12 ã«æããšã®èŠè§Šèšº èžéšãžã®æŸå°ç·æ²»çã®æ¢åŸãã 8ïœ10 幎åŸãŸã㯠40 æ³ã®ããããæ©ãææããéå§
å®æçãªèªå·±æ€èšºãå§ãããã g
浞最æ§ä¹³çã® 5 幎 ãªã¹ã¯ã35 æ³ä»¥äžã®å¥³æ§ã§ 1.7ïŒ ä»¥äž c
æ¯å¹Žã®ãã³ã¢ã°ã©ã ïŒ6ïœ12 ã«æããšã®èŠè§Šèšº å®æçãªèªå·±æ€èšºãå§ãããã g ãªã¹ã¯äœæžæŠç¥ãèæ ®ãã ïŒNCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §ïŒ
25 æ³æªæº h
25 æ³ä»¥äž h
匷åãªå®¶ææŽ d ãŸã㯠éºäŒççŽ å e,f
æ¯å¹Žã®èŠè§Šèšº å®æçãªèªå·±æ€èšºãå§ãããã g
æ¯å¹Žã®ãã³ã¢ã°ã©ã ïŒ6ïœ12 ã«æããšã®èŠè§Šèšº éºäŒæ§ä¹³çã»åµå·£çïŒHBOCïŒf æ£è ã§ã¯ 25 æ³ããéå§ åŒ·åãªå®¶ææŽãŸãã¯ãã®ä»ã®éºäŒççŽ å ãããå Žå㯠幎å°ã®ä¹³çäŸã® 5ïœ10 幎åããéå§
å®æçãªèªå·±æ€èšºãå§ãããã g ãã³ã¢ã°ã©ã ãšèŠè§Šèšºã®è£å©ãšã㊠MRI ãèæ ®ãã ãªã¹ã¯äœæžæŠç¥ãèæ ®ãã ïŒNCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §ïŒ
LCIS/ ALH
æ¯å¹Žã®ãã³ã¢ã°ã©ã ïŒ6ïœ12 ã«æããšã®èŠè§Šèšº ãªã¹ã¯äœæžæŠç¥ãèæ ®ãã ïŒNCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §ïŒ
å®æçãªèªå·±æ€èšºãå§ãããã g
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³èª¿æ»ã»ã¯ã·ã§ã³ãåç § 以åã®ä¹³çæŽ
èŠè§Šèšºãåç §ïŒBSCR-1ïŒ
ãã³ã¢ã°ã©ãã£è©äŸ¡ã åç §ïŒBSCR-15ïŒ
c ä¿®æ£Gail ã¢ãã«ã§çšããããå±éºå åãåç §ïŒBSCR-BïŒ d 匷åãªå®¶ææŽã®å®çŸ©ã«ã€ããŠã¯NCCN éºäŒç/家ææ§ãã€ãªã¹ã¯è©äŸ¡ã¬ã€ãã©ã€ã³
ãåç § e ã¢ã¡ãªã«èšåºè «çåŠäŒã¬ã€ãã©ã€ã³ã«ããã æ°ã®å®çŸ©ã®ãšããïŒã¢ã¡ãªã«èšåºè «
çåŠäŒã®å£°æïŒ1996 幎2 æ20 æ¥æ¡æã®ãçæåæ§ã«é¢ããéºäŒåæ€æ»ããJ Clin Oncol14(5):1730-1736, 1996.ïŒ
f NCCN éºäŒç/家ææ§ãã€ãªã¹ã¯è©äŸ¡ã¬ã€ãã©ã€ã³ãåç § g 女æ§ã¯èªåã®ä¹³æ¿ã®ããšãããç¥ã£ãŠããã¹ãã§ãããå€åãèŠã€ãããå³åº§ã«
䞻治å»ã«å ±åããªããã°ãªããªããå®æçã«äžè²«ããèªå·±æ€èšºïŒBSEïŒãè¡ã£ãŠ
ãããšãèªåã®ä¹³æ¿ã®ããšãããåããããã«ãªããéçµåã®å¥³æ§ã®å Žåã¯BSE ãçççµäºæã«è¡ãã®ã ãæçã§ããã
h æ£è ã«ãã£ãŠã¯ãã£ãšæ©æã®ã¹ã¯ãªãŒãã³ã°ãé©åãªå Žåãããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-3
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
蚺æã«ããŽãªãŒ
èŠè§Šèšº èŠè§Šèšºã§ã® éœæ§æèŠ
ããã/è «ç€
ä¹³é åæ³ã觊ç¥å¯èœãªè «ç€ãªã
é察称æ§é°åœ±/ å°çµç¯åœ¢æ
ç®èã®å€åïŒ æ©ç®ç¶ç®è çŽ æ ä¹³é è¡šç®å¥é¢ èœå±ã湿ç¹
30 æ³ä»¥äž
30 æ³æªæº
远跡è©äŸ¡ãåç §ïŒBSCR-4ïŒ
远跡è©äŸ¡ãåç §ïŒBSCR-8ïŒ
蚺æã®è¿œè·¡ãåç §ïŒBSCR-12ïŒ
蚺æã®è¿œè·¡ãåç §ïŒBSCR-13ïŒ
蚺æã®è¿œè·¡ãåç §ïŒBSCR-14ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-4
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
çºçŸããŠãã城å/çç¶ åæè©äŸ¡ 远跡è©äŸ¡ 30 æ³ä»¥äž
i è¶ é³æ³¢ã®æ¹ãæãŸããèšåºç¶æ³ã¯å°ãªãïŒããšãã°åçŽå¢èãçãããå ŽåïŒ j ãã³ã¢ã°ã©ãã£è©äŸ¡ã®ã«ããŽãªãŒå®çŸ©ãåç §ïŒBSCR-CïŒ k ãã³ã¢ã°ã©ãã£çµæã¯å¿ ã çµè©äŸ¡ã«ããŽãªãŒã䜿ã£ãŠå ±åããªããã°ãªããªãïŒãã³ã¢ã°ã©ãã£å質åºæºæ³ã çµèŠåãå®å ±62(208):55988, 1977ïŒ l èšåºæèŠãšç»å蚺ææèŠã®äœçœ®ççžé¢ãè©äŸ¡ãããçžé¢ããªããã°ã«ããŽãªãŒ1ïœ3 ã«æ»ã£ãŠè§Šç¥å¯èœç å€ã®ãããªã粟å¯æ€æ»ãè¡ããç»å蚺ææèŠã觊蚺æèŠãšçžé¢ããŠããã°ã
ç»åäžã®åé¡ã®ç²Ÿå¯æ€æ»ã«ãã£ãŠè§Šèšºã§ã®åé¡ã®è§£çãåŸãããã m è¡ç®¡ã®æµããèªããããªãäœãšã³ãŒæ§ã®äžžãéå±æ§ã®è «ç€ã§ããã¹ãŠã§ã¯ãªããåçŽå¢èã®åºæºãã»ãšãã©æºãããŠããã
ããã/è «ç€ 30 æ³ä»¥äž
BI-RADS® ã«ããŽãªãŒ 1ïœ3j,k
è¶ é³æ³¢
å å®æ§
å¢è
äžç¢ºå®ãŸã㯠çããã
ããããè¯æ§æèŠ
çµç¹çæ€ãåç §ïŒBSCR-5ïŒ
è¶ é³æ³¢æèŠãåç §ïŒBSCR-6ïŒ
çåæ§ãŸã㯠éåçŽå¢è m
éçåæ§ã〠åçŽå¢è
è¶ é³æ³¢æ€æ»ã§ç°åžžãèª
ããããªã
çåæ§ãŸãã¯äžç¢ºå®ã®å Žåã¯ç©¿åºåžåŒçŽ°è蚺ïŒè¶ é³æ³¢ã¬ã€ãã³ã¢çæ€ãã¯ãªããç眮ã蚺æã«åœ¹ç«ã€ããšãããããè¶ é³æ³¢ã§äžèŠåãªå¢èå£ãŸãã¯å¢èå ã®è «ç€ã®æèŠãããã°ãå€ç§çåé€ãæãŸããïŒ
å€åãããã°æ£è ã«å ±åããŠãããããã«ããŠå€§ããã 2ïœ4 ã«æé芳å¯
çµç¹çæ€ ãŸã㯠3ïœ6 ã«æããšã® çµé芳å¯Â±ç»å蚺æã 1ïœ2 幎å®æœããŠå€§ãããè©äŸ¡
ç©¿åºåžåŒçŽ°è蚺 æèŠãåç § ïŒBSCR-7ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãå ç §ïŒBSCR-1ïŒ
çµç¹çæ€ãåç § ïŒBSCR-5ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã åç §ïŒBSCR-1ïŒ
èŠè§Šèšºã§é²è¡ãŸãã¯å€§ããã®å¢å€§
äžå€
ãã³ã¢ã°ã©ã i
BI-RADS® ã«ããŽãªãŒ 4ïœ5j,k,l
蚺æãã³ã¢ã°ã©ã ã®è¿œè·¡ãåç §ïŒBSCR-16ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-5
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
è¶ é³æ³¢æèŠ è¿œè·¡è©äŸ¡ 30 æ³ä»¥äž
n FNA ããã³ã³ã¢ïŒéãŸãã¯ç空æ¯æŽïŒçæ€ã¯ãã¹ãŠæçšã§ãããFNA ã«ã¯çŽ°è蚺æè¡ãå¿ èŠã§ããã o è¿œå çµç¹ãå¿ èŠãªå Žåã®ãããã®ä»ã®çµç¹åŠïŒã ãã³ç£çç å€ãèç¶è «çã®å¯èœæ§ãä¹³é ç å€ãæŸå°ç¶ç¢çãŸãã¯ç çå»ãæžå¿µãããã®ä»ã®çµç¹åŠã
å å®æ§ïŒ äžç¢ºå®ãŸã㯠çããã
çµç¹çæ€
ã³ã¢éçæ€ n ïŒæãŸããïŒ ãŸã㯠åé€ ïŒã³ã¢éçæ€ãã§ããªãå ŽåïŒ
è¯æ§ã§ç»åæèŠã äžèŽ
6ïœ12 ã«æããšã®èŠè§ŠèšºÂ±è¶ é³æ³¢/ãã³ã¢ã°ã©ã ã1ïœ2 幎å®æœããŠå®å®æ§ãè©äŸ¡
äžç¢ºå® ãŸãã¯
ALHo ãŸãã¯
è¯æ§ã ãç»åæ èŠãäžäžèŽ ãŸãã¯
LCIS
å€ç§çåé€
è¯æ§
ALH
LCIS æªæ§
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç § ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒ ããã³ NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
以äžã®è©²åœãããããŒããã©ã
æªæ§
è¯æ§
ALH
LCIS
æªæ§
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³çãªã¹ã¯äœæžããã³ ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
倧ããã®å¢å€§
å®å®
ããã/å¡ã30 æ³æªæºã åæè©äŸ¡ã«æ»ãïŒBSCR-4ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-6
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
è¶ é³æ³¢æèŠ è¿œè·¡è©äŸ¡ 觊ç¥å¯èœãªããã/è «ç€
n FNA ããã³ã³ã¢ïŒéãŸãã¯ç空æ¯æŽïŒçæ€ã¯ãã¹ãŠæçšã§ãããFNA ã«ã¯çŽ°è蚺æè¡ãå¿ èŠã§ããã o è¿œå çµç¹ãå¿ èŠãªå Žåã®ãããã®ä»ã®çµç¹åŠïŒã ãã³ç£çç å€ãèç¶è «çã®å¯èœæ§ãä¹³é ç å€ãæŸå°ç¶ç¢çãŸãã¯ç çå»ãæžå¿µãããã®ä»ã®çµç¹åŠã p Stavros A, Thickman D, Rapp C ã. å å®æ§ä¹³æ¿å°çµç¯ïŒè¯æ§ããã³æªæ§ç å€ãåºå¥ããããã®è¶ é³æ³¢æ€æ»ã®å©çš. Radiology 1995;196:123-124.
芳å¯ïŒ2ïœïœæªæºã§èšåºçã« æªæ§ã®çããäœãå ŽåïŒ
6ïœ12 ã¶æããšã®èŠè§Šèšºããã³è¶ é³æ³¢Â±ãã³ã¢ã°ã©ã ã 1ïœ2 幎å®æœããŠãå®å®æ§ãè©äŸ¡
å å®æ§ïŒ ãããã è¯æ§æèŠ p
倧ããã®å¢å€§
å®å®
çµç¹çæ€ãåç § ïŒBSCR-5ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã åç §ïŒBSCR-1ïŒ
çµç¹èšºæ
ã³ã¢éçæ€ n ïŒæãŸããïŒ
åé€ïŒã³ã¢é
çæ€ãã§ã
ãªãå ŽåïŒ
è¯æ§ã§ç»å æèŠãäžèŽ
6ïœ12 ã«æããšã®èŠè§ŠèšºÂ±è¶ é³æ³¢/ãã³ã¢ã°ã©ã ã1ïœ2 幎å®æœããŠå®å®æ§ãè©äŸ¡
倧ããã®å¢å€§
å®å®
çµç¹çæ€ãåç § ïŒBSCR-5ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒã ã³ã°ãåç §ïŒBSCR-1ïŒ
äžç¢ºå®ãŸã㯠ALHo
ãŸãã¯LCISo ãŸãã¯è¯æ§ã ãç»åæèŠãäžäžèŽ
å€ç§çåé€
æªæ§ NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
è¯æ§ ALH LCIS æªæ§
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã åç §ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã° ïŒBSCR-1ïŒããã³ NCCNä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³çãªã¹ã¯äœæžããã³ ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-7
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ç©¿åºåžåŒçŽ°è蚺æèŠ è¿œè·¡è©äŸ¡ ããã/è «ç€
o è¿œå çµç¹ãå¿ èŠãªå Žåã®ãããã®ä»ã®çµç¹åŠïŒã ãã³ç£çç å€ãèç¶è «çã®å¯èœæ§ãä¹³é ç å€ãæŸå°ç¶ç¢çãŸãã¯ç çå»ãæžå¿µãããã®ä»ã®çµç¹åŠã q ã«ãŒãã³ã®çŽ°è蚺ã¯å§ããããªãã
æ¶²äœ ïŒå¢èïŒ
è «ç€ãåç¶ãŸãã¯è¡æ¶²æ§ã®æ¶²äœ
è «ç€ãæ¶å€±ãã€éè¡æ¶²æ§ã®æ¶²äœ q
è¶ é³æ³¢ïŒç»åã¬ã€ãäžçæ€ ãŸã㯠å€ç§çåé€
è¯æ§ã§ç»åæèŠãäžèŽ
6ïœ12 ã«æããšã®èŠè§ŠèšºÂ±è¶ é³æ³¢/ãã³ã¢ã°ã©ã ã1ïœ2 幎å®æœããŠå®å®æ§ãè©äŸ¡
倧ããã®å¢å€§
çµç¹ãµã³ããªã³ã° ãåç §ïŒBSCR-5ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
å®å®
äžç¢ºå®ãŸã㯠ALHo ãŸãã¯LCIS ãŸãã¯è¯æ§ã ãç»åæèŠãäžäžèŽ
å€ç§çåé€
æªæ§ NCCNä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
è¶ é³æ³¢ ïŒ30 æ³ä»¥äžã¯BSCR-4 ãåç §ïŒãŸã㯠ïŒ30 æ³æªæºã¯BSCR-9 ãåç §ïŒ ãŸã㯠å€ç§çåé€
è¯æ§ ALH LCIS æªæ§
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³NCCN ä¹³çãªã¹ã¯äœæžããã³ ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
2ïœ4 ã«æã®è¿œè·¡
è «ç€ãåçº
æ€æ»é°æ§ ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-8
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
çºçŸããŠãã城å/çç¶ åæè©äŸ¡ 远跡è©äŸ¡ 30 æ³æªæº
ããã/è «ç€ 30 æ³æªæº
è¶ é³æ³¢ ïŒæãŸããïŒ ãŸã㯠éçæ€ ãŸã㯠ççåšæ 1ïœ2 åã®èŠ³å¯ïŒèšåºççããäœãå Žåã®éžæè¢ïŒ
液äœãªã
液äœïŒå¢èïŒ
è «ç€ãæ¶å€±
è «ç€ãåç¶
è¶ é³æ³¢
FNA
è¶ é³æ³¢æèŠãåç §ïŒBSCR-9ïŒ
è¶ é³æ³¢æèŠãåç §ïŒBSCR-9ïŒ
ç©¿åºåžåŒçŽ°è蚺æèŠãåç §ïŒBSCR-10ïŒ
ç©¿åºåžåŒçŽ°è蚺æèŠãåç §ïŒBSCR-7ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
è¶ é³æ³¢ïŒäžã®ãããŒãåç §ïŒ ãŸã㯠éçæ€ïŒäžã®ãããŒãåç §ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-9
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
çºçŸããŠãã城å/çç¶ åæè©äŸ¡ 远跡è©äŸ¡ 30 æ³æªæº
m è¡ç®¡ã®æµããèªããããªãäœãšã³ãŒæ§ã®äžžãéå±æ§ã®è «ç€ã§ããã¹ãŠã§ã¯ãªããåçŽå¢èã®åºæºãã»ãšãã©æºãããŠããã
ããã/è «ç€ 30 æ³æªæº
è¶ é³æ³¢ ïŒæãŸããïŒ
å å®æ§
å¢è
ç å€ã¯èŠèŠåããã
äžç¢ºå®ãŸãã¯çããã
çåæ§ãŸã㯠éåçŽå¢è m
ãã³ã¢ã°ã©ã ãèæ ®ãã
ããããè¯æ§æèŠ
éçåæ§ãã€åçŽå¢è
è¶ é³æ³¢æèŠãåç §ïŒBSCR-11ïŒ
è¶ é³æ³¢æèŠãåç §ïŒBSCR-6ïŒ
çåæ§ãŸãã¯äžç¢ºå®ã®å Žåã¯ç©¿åºåžåŒçŽ°è蚺ïŒè¶ é³æ³¢ã§äžèŠåãªå¢èå£ãŸãã¯å¢èå ã®è «ç€ã®æèŠãããã°å€ç§çåé€ãæãŸããïŒ
å€åãããã°æ£è ã«å ±åããŠãããããã«ããŠå€§ããã 2ïœ4 ã«æé芳å¯
çµç¹çæ€ ãŸã㯠3ïœ6 ã«æããšã®èŠ³å¯Â±ç»å蚺æã 1ïœ2 幎å®æœããŠå€§ãããè©äŸ¡
ç©¿åºåžåŒçŽ°è蚺æèŠãåç § ïŒBSCR-7ïŒ
çµç¹çæ€ãåç § ïŒBSCR-5ïŒ
ã«ãŒãã³ã¹ã¯ ãªãŒãã³ã°ãå ç §ïŒBSCR-1ïŒ
倧ããã®å¢å€§
å®å®
倧ããã®å¢å€§
å®å®
çµç¹çæ€ãåç § ïŒBSCR-5ïŒ
ã«ãŒãã³ã¹ã¯ ãªãŒãã³ã°ãå ç §ïŒBSCR-1ïŒ
ããã/å¡ã30 æ³æªæºã åæè©äŸ¡ã«æ»ãïŒBSCR-8ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-10
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ç©¿åºåžåŒçŽ°è蚺 远跡è©äŸ¡ ããã/å¡ 30 æ³æªæº
o è¿œå çµç¹ãå¿ èŠãªå Žåã®ãããã®ä»ã®çµç¹åŠïŒã ãã³ç£çç å€ãèç¶è «çã®å¯èœæ§ãä¹³é ç å€ãæŸå°ç¶ç¢çãŸãã¯ç çå»ãæžå¿µããä»ã®çµç¹åŠã r 倧ãããæ£ç¢ºã«ã¢ãã¿ãªã³ã°ããããã®å€§ãã枬å®å€ãåŸãããã«è¶ é³æ³¢ãèæ ®ããã
液äœãªã çµç¹åŠ/现è蚺
äžç¢ºå®
è¯æ§
çµç¹ãäžåå
éå®åæ§ o
æªæ§
è¶ é³æ³¢ãèæ ®ãã
è¶ é³æ³¢æèŠãåç §ïŒBSCR-9ïŒ
ãã³ã¢ã°ã©ã ïŒè¶ é³æ³¢
çµç¹çæ€ãåç §ïŒBSCR-11ïŒ
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
3ïœ6 ã«æããšã« 1ïœ2 幎éèŠ³å¯ ãŸã㯠å€ç§çåé€ ïŒãããã倧ããã®å ŽåïŒ
å床ãµã³ãã«æ¡åãè¡ã
倧ãã ã®å¢å€§
å®å®
çµç¹çæ€ãåç § ïŒBSCR-11ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒ ãã³ã°ãåç § ïŒBSCR-1ïŒ
çµç¹çæ€ãåç §ïŒBSCR-11ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-11
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
è¶ é³æ³¢æèŠ è¿œè·¡è©äŸ¡ 觊ç¥å¯èœãªããã/å¡ 30 æ³æªæº
n FNA ããã³ã³ã¢ïŒéãŸãã¯ç空æ¯æŽïŒçæ€ã¯ãã¹ãŠæçšã§ãããFNA ã«ã¯çŽ°è蚺æè¡ãå¿ èŠã§ããã o è¿œå çµç¹ãå¿ èŠãªå Žåã®ãããã®ä»ã®çµç¹åŠïŒã ãã³ç£çç å€ãèç¶è «çã®å¯èœæ§ãä¹³é ç å€ãæŸå°ç¶ç¢çãŸãã¯ç çå»ãæžå¿µãããã®ä»ã®çµç¹åŠã
å å®æ§ïŒ äžç¢ºå®ãŸã ã¯çããã
ãã³ã¢ ã°ã©ã
çµç¹ çæ€
ã³ã¢éçæ€ n ïŒæãŸããïŒ ãŸã㯠åé€
è¯æ§ã§ç»åæèŠ ãäžèŽ
äžç¢ºå®ãŸãã¯ALHo ãŸãã¯LCISãŸãã¯è¯æ§ã ãç»åæèŠãäžäžèŽ
6ïœ12 ã«æããšã® èŠè§ŠèšºÂ±è¶ é³æ³¢/ãã³ã¢ã°ã©ã ã 1ïœ2 幎å®æœããŠå®å®æ§ãè©äŸ¡
倧ããã®å¢å€§
çµç¹çæ€ã«æ»ã
å®å®
è¯æ§
ALH
LCIS
æªæ§
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç § ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã° ïŒBSCR-1ïŒããã³ NCCN ä¹³ç ãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³çãªã¹ã¯äœæžããã³ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
å€ç§çåé€
è¯æ§
ALH
LCIS
æªæ§
æªæ§
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³çãªã¹ã¯äœæžããã³ ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
ã¹ã¯ãªãŒãã³ã°ã«ããŽãªãŒ ã«æ»ãïŒBSCR-4ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-12
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
蚺æã«ããŽãªãŒ 蚺æ远跡
s ä¹³é åæ³ãåŒãèµ·ããåŸãè¬ç©ã®äžèŠ§ïŒç¶²çŸ çã§ã¯ãªãïŒïŒå粟ç¥è¬ãæé«è¡å§è¬ããªããšãŒããçµå£é¿åŠè¬ããšã¹ããã²ã³ã j ãã³ã¢ã°ã©ãã£è©äŸ¡ã®ã«ããŽãªãŒå®çŸ©ãåç §ïŒBSCR-CïŒ k ãã³ã¢ã°ã©ãã£çµæã¯å¿ ã çµè©äŸ¡ã«ããŽãªãŒã䜿ã£ãŠå ±åããªããã°ãªããªãïŒãã³ã¢ã°ã©ãã£å質åºæºæ³ã çµèŠåãå®å ±62(208):55988, 1977ïŒ
ãã³ã¢ã°ã©ã ä¹³æ¿ã®å§è¿«ãæ¢ããèªçºçåæ³ãããã°å ±åãããã
æå°ãã
BI-RADS® ã«ããŽãªãŒj,k1ïœ3 乳管åé€ ä¹³ç®¡é 圱
ïŒä»»æïŒ
èŠ³å¯ ä¹³æ¿ã®å§è¿«ãæ¢ããèªçºçåæ³ãããã°å ±åããããæå°ãã
ä¹³é åæ³ sã 觊ç¥å¯èœãª è «ç€ãªã
éèªçºçå€ä¹³ç®¡æ§
æç¶çã蚺å¯ã§åçŸæ§ããããèªçºçãçåŽæ§ãã€æŒ¿æ¶²æ§ãè¡æ¶²æ§ãŸãã¯æŒ¿æ¶²è¡æ¶²ç¶ã
40 æ³æªæº
40 æ³ä»¥äž
ãã³ã¢ã°ã©ã
BI-RADS® ã«ããŽãªãŒj,k4ïœ5
ã«ããŽãªãŒ4ïœ5 㮠粟å¯æ€æ»ãåç §ïŒBSCR-16ïŒ
è¯æ§/ äžç¢ºå®
NCCN ä¹³çæ²»ç ã¬ã€ãã©ã€ã³ã åç §
æªæ§
ãã³ã¢ã°ã©ãã£ã®è©äŸ¡ïŒBSCR-15ïŒãåç §
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-13
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
蚺æã«ããŽãªãŒ 蚺æ远跡
é察称æ§é°åœ± ãŸãã¯å°çµ ç¯åœ¢æ
30 æ³æªæº
30 æ³ä»¥äž
èšåºçã«å¿ èŠãªå Žåã¯è¶ é³æ³¢Â±ãã³ã¢ã°ã©ã èšåºçã«å¿ èŠãªå Žåã¯äž¡åŽã® ãã³ã¢ã°ã©ã Â±è¶ é³æ³¢
BI-RADS® ã«ããŽãªãŒ1ïœ3ããã³/ãŸãã¯ è¶ é³æ³¢é°æ§ ãŸãã¯åçŽå¢è
BI-RADS® ã«ããŽãªãŒ4ïœ5ããã³/ãŸã㯠å å®æ§ãŸã㯠éåçŽå¢è
èšåºçã« çããã
èšåºçã«è¯æ§ãšè©äŸ¡ããã
çµç¹çæ€ãåç § ïŒBSCR-5 ãŸã㯠BSCR-11ïŒ
çµç¹çæ€ãåç § ïŒBSCR-5 ãŸã㯠BSCR-11ïŒ
3ïœ6 ã«æç®ã«èŠè§Šèšº
å®å®
é²è¡
ã«ãŒãã³ã¹ã¯ãªãŒ ãã³ã°ãåç §ïŒBSCR-1ïŒ
ããã/è «ç€ã® ãããŒãåç §ïŒBSCR-3ïŒ
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-14
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
蚺æã«ããŽãªãŒ 蚺æ远跡
m è¡ç®¡ã®æµããèªããããªãäœãšã³ãŒæ§ã®äžžãéå±æ§ã®è «ç€ã§ããã¹ãŠã§ã¯ãªããåçŽå¢èã®åºæºãã»ãšãã©æºãããŠããã n FNA ããã³ã³ã¢ïŒéãŸãã¯ç空æ¯æŽïŒçæ€ã¯ãã¹ãŠæçšã§ãããFNA ã«ã¯çŽ°è蚺æè¡ãå¿ èŠã§ããã t ããã¯ä¹³æ¿ã®æ·±å»ãªçŸæ£ã瀺ããŠããããšããããããè©äŸ¡ïŒ7ïœ10 æ¥ïŒãå¿ èŠã§ããã u èšåºçã«çããäœããã°ãä¹³è ºçã«å¯Ÿããæçç©è³ªã®çæè©Šçšãé©å¿ãšãªãã
ãã³ã¢ã°ã©ã Â±è¶ é³æ³¢
BI-RADS® ã«ããŽãªãŒ4ïœ5 ããã³/ãŸã㯠å å®æ§ãŸã㯠éåçŽå¢è m
BI-RADS® ã«ããŽãªãŒ1ïœ3u ããã³/ãŸãã¯ è¶ é³æ³¢é°æ§ãŸãã¯åçŽå¢è
ç®èã®ãã³ã çæ€ãŸã㯠乳é çæ€
è¯æ§
æªæ§
èšåºçãç çæèŠççžé¢ãåè©äŸ¡ u åçæ€ãèæ ® ä¹³æ¿å°éå»ãžã®çžè«ãèæ ®
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
ã³ã¢éçæ€ n ïŒæãŸããïŒn ±ãã³ãçæ€ ãŸã㯠å€ç§çåé€ ïŒè¿èå è «ç€ãå£è¥åïŒ
è¯æ§
æªæ§
æªå®æœãªãç®èã®ãã³ãçæ€ãŸãã¯ä¹³é çæ€
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
æªæ§
è¯æ§äžã®è¯æ§ã® ãããŒãåç §
ç®èã®å€åïŒt æ©ç®ç¶ç®è çŽ æ ä¹³é è¡šç®å¥é¢ èœå±ã湿ç¹
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-15
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
è©äŸ¡ã«ããŽãªãŒj,k 蚺æãã³ã¢ã°ã©ã ã®è¿œè·¡
j ãã³ã¢ã°ã©ãã£è©äŸ¡ã®ã«ããŽãªãŒå®çŸ©ãåç §ïŒBSCR-CïŒ k ãã³ã¢ã°ã©ãã£çµæã¯å¿ ã çµè©äŸ¡ã«ããŽãªãŒã䜿ã£ãŠå ±åããªããã°ãªããªãïŒãã³ã¢ã°ã©ãã£å質åºæºæ³ã çµèŠåãå®å ±62(208):55988, 1977ïŒ
ãã³ã¢ã°ã©ãã£è©äŸ¡
BI-RADS®ã«ããŽãªãŒ3ããããè¯æ§æèŠ
BI-RADS®ã«ããŽãªãŒ2è¯æ§æèŠ
BI-RADS®ã«ããŽãªãŒ1é°æ§
BI-RADS®ã«ããŽãªãŒ0 ä»å çç»å蚺æè©äŸ¡ãå¿ èŠ
BI-RADS®ã«ããŽãªãŒ4 ç°åžžãçããã BI-RADS®ã«ããŽãªãŒ5 æªæ§çŸæ£ãé«åºŠã«ç€ºåããã
BI-RADS®ã«ããŽãªãŒ6 æªæ§çŸæ£ãçæ€ã§èšŒææžã¿
以åã®ãã£ã«ã ãšã®æ¯èŒãå«ã蚺æ粟å¯æ€æ»ããã³/ãŸãã¯èšºæãã³ã¢ã°ã©ã Â±å¿ èŠã«å¿ããè¶ é³æ³¢
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç § ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç § ïŒBSCR-1ïŒ
6 ã«æç®ã®èšºæãã³ã¢ã°ã©ã ããã®åŸã¯ 6ïœ12 ã«æããšã« 1ïœ2 幎éãåæ¥é¢ã確å®ã§ ãªãã£ããæ£è ã®äžå®ã倧ããå Žåã¯çæ€ãå«ãã
蚺æãã³ã¢ã°ã©ã ã®è¿œè·¡ãåç §ïŒBSCR-16ïŒ
ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
該åœãã çµè©äŸ¡ã«ããŽãªãŒãåç §
å®å®ãŸãã¯æ¶å€±
çãã®å¢å€§
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
ã«ããŽãªãŒ4ïœ5 㮠蚺æãã³ã¢ã°ã©ã ã®è¿œè·¡ãåç §ïŒBSCR-16ïŒ
ãã³ã¢ã°ã©ã ã®èæ ®ç¹ïŒ ãã³ã¢ã°ã©ã ã®ç®çãã¹ã¯ãªãŒãã³ã°
ã蚺æããç¹å®ãã 以åã®ã³ããŒã§ãªãïŒåæ¬ã®ïŒ ãã£ã«ã ãããã°ããããšæ¯èŒãã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-16
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
è©äŸ¡ã«ããŽãªãŒj,k 蚺æãã³ã¢ã°ã©ã ã®è¿œè·¡
j ãã³ã¢ã°ã©ãã£è©äŸ¡ã®ã«ããŽãªãŒå®çŸ©ãåç §ïŒBSCR-CïŒ k ãã³ã¢ã°ã©ãã£çµæã¯å¿ ã çµè©äŸ¡ã«ããŽãªãŒã䜿ã£ãŠå ±åããªããã°ãªããªãïŒãã³ã¢ã°ã©ãã£å質åºæºæ³ã çµèŠåãå®å ±62(208):55988, 1977ïŒ n FNA ããã³ã³ã¢ïŒéãŸãã¯ç空æ¯æŽïŒçæ€ã¯ãã¹ãŠæçšã§ãããFNA ã«ã¯çŽ°è蚺æè¡ãå¿ èŠã§ããã o è¿œå çµç¹ãå¿ èŠãªå Žåã®ãããã®ä»ã®çµç¹åŠïŒã ãã³ç£çç å€ãèç¶è «çã®å¯èœæ§ãä¹³é ç å€ãæŸå°ç¶ç¢çãŸãã¯ç çå»ã®ãæžå¿µãããã®ä»ã®çµç¹åŠã
6ïœ12 ã«æåŸã«èšºæãã³ã¢ã°ã©ã
ã«ãŒãã³ ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
å€ç§çåé€ è¿œè·¡ãåç § ïŒBSCR-17ïŒ
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
6ïœ12 ã«æåŸã« ãã³ã¢ã°ã©ã
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç § ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³ç ãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³ç ãªã¹ã¯äœæžããã³ ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
BI-RADS®
ã«ããŽãªãŒ4 ç°åžžãçããã BI-RADS®
ã«ããŽãªãŒ5 æªæ§çŸæ£ãé«åºŠã«ç€ºåããã
ã³ã¢éçæ€ n ïŒæãŸããïŒ ãŸãã¯
ç çæèŠ/ ç»åãäžèŽ
ç çæèŠ/ ç»åãäžäžèŽ
åè©äŸ¡ã åç»å蚺æïŒ å¿ èŠã«å¿ã㊠远å çµç¹ãæ¡å
ç çæèŠ/ ç»åãäžèŽ
ç çæèŠ/ ç»åããŸã äžäžèŽ
è¯æ§
ALH ãŸã㯠LCIS ãŸãã¯ãã®ä»ã®ç çæèŠ o
æªæ§
ããã¯ã¯ã€ã€ãŒæ¿å ¥äžåé€çæ€ïŒæšæ¬ X ç·åç
å€ç§çåé€ è¿œè·¡ãåç §ïŒBSCR-17ïŒ
è¯æ§
ALH
LCIS
æªæ§
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-17
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
远跡è©äŸ¡
å€ç§çåé€
è¯æ§
ALH
LCIS
æªæ§
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãåç §ïŒBSCR-1ïŒ
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ãåç §
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ïŒBSCR-1ïŒããã³ NCCN ä¹³çãªã¹ã¯äœæžããã³ ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ãåç §
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-A
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
1 Pisano ED, Gatsonis C, Hendrick Eãã®ããžã¿ã«ãã³ã¢ã°ã©ãã£ç»åã¹ã¯ãªãŒãã³ã°è©ŠéšïŒDigital Mammographic Imaging Screeing Trial:
DMISTïŒæ²»éšè²¬ä»»å»åž«ãDiagnostitc performance of digital versus film mammography for breast cancer screening.N Engl J Med 2005;353:1773-1783ã èŠè§Šèšºã«æ»ãïŒBSCR-1ïŒ
ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ã®èæ ®ç¹
寿åœãå¶éããé床ã®å䜵ç æ ããã³æ²»ççä»å ¥ãèšç»ãããŠãããã©ãããèæ ®ã
ã ã¹ã¯ãªãŒãã³ã°å¹Žéœ¢ã®äžéã¯ãŸã 確ç«ãããŠããªãã çŸåšã®ãšããã³ã¹ã¯ãã¹ã¯ãªãŒãã³ã°æé ãšããŠã®ä¹³æ¿ã·ã³ãã°ã©ãã£ïŒããšãã°ã»
ã¹ã¿ããã¹ãã£ã³ïŒã乳管æŽæµã®ã«ãŒãã³äœ¿çšãæ¯æããŠããªãã çŸåšã®ãšããã³ã¹ã¯ãå¹³åçãªã¹ã¯ã®å¥³æ§ã«ãããã¹ã¯ãªãŒãã³ã°æé ãšããŠã®ä¹³æ¿
MRI ã®ã«ãŒãã³äœ¿çšãæ¯æããŠããªãã é«ãªã¹ã¯å¥³æ§ã®ãã³ã¢ã°ã©ãã£ã®è£å©ãšããŠã®ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ã®ããã® MRI ã®äœ¿çšãæ¯æããããŒã¿ã¯éãããŠããã
é«ãªã¹ã¯å¥³æ§ãŸãã¯ä¹³æ¿çµç¹ãçš å¯ãªå¥³æ§ã«å¯Ÿããä¹³çã¹ã¯ãªãŒãã³ã°ã«ãããŠãã
ã³ã¢ã°ã©ãã£ã®è£å©ãšããŠè¶ é³æ³¢ã䜿çšããããšãæ¯æããããŒã¿ã¯éãããŠããã
1 è©ŠéšïŒDMISTïŒãããè¥å¹Žå¥³æ§ããã³ä¹³æ¿çµç¹ãçš å¯ãªå¥³æ§ã«ãããããžã¿ã«ãã³
ã¢ã°ã©ãã£ã®æçæ§ã瀺åããã 1ã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã BSCR-B
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
1 詳ããæ å ±ã¯www.nci.nih.gov.ãåç §ã 2 çŸåšã®Gail ã¢ãã«ã§ã¯ãçœäººä»¥å€ã®å¥³æ§ã®ä¹³çãªã¹ã¯ãæ£ç¢ºã«è©äŸ¡ã§ããªãããšãããã
ä¿®æ£ Gail ã¢ãã«ã§çšããããå±éºå å 1
çŸåšã®å¹Žéœ¢ å朮幎霢 åçç£å¹Žéœ¢ãŸãã¯æªçµç£ ä¹³çã®äžç芪è¡çžè ã®æ° 以åã®è¯æ§ä¹³æ¿çæ€çµæã®åæ° ä»¥åã®ä¹³æ¿çæ€ã§ã® ALH 人皮 2
ãªã¹ã¯èšç®çšãä¿®æ£Gail ã¢ãã«ã«åºã¥ããwww.nci.nih.gov.ãåç §ã
Guidelines Index Breast Screening TOC
MS, References
BSCR-C
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã 2 ã® 1
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ãã³ã¢ã°ã©ãã£è©äŸ¡ã«ããŽãªãŒã®å®çŸ© 1,2 A è©äŸ¡ãæªäºïŒ
ã«ããŽãªãŒ0ïŒè¿œå ç»å蚺æè©äŸ¡ããã³/ãŸãã¯æ¯èŒã®ããã®ä»¥åã®ãã³ã¢ã°ã©ã ãå¿ èŠïŒ è¿œå è©äŸ¡ãå¿ èŠãªæèŠãããã¯ã»ãšãã©åžžã«ã¹ã¯ãªãŒãã³ã°ç¶æ³ã§çšãããããäžå®ã®ç¶æ³ã§ã¯ãå®å šãªãã³ã¢ã°ã©ãã£ç²Ÿå¯æ€æ»ã®åŸã«ãã®ã«ããŽãªãŒ
ãçšããããããšããããè¿œå ç»å蚺æè©äŸ¡ã®æšå¥šã«ã¯ãã¹ãããå§è¿«ãæ¡å€§ãç¹æ®ãã³ã¢ã°ã©ãã£åããã³è¶ é³æ³¢ãå«ãŸãããããããã«éããªãã
æ€æ»ãé°æ§ã§ãªããå žåçãªè¯æ§æèŠãå«ãŸããŠããªãå Žåã«ã¯ãå¯èœãªéããçŸåšã®æ€æ»ãšéå»ã®æ€æ»ãæ¯èŒãããæŸå°ç·ç§å»ã¯ã以åã®æ€æ»ãã©
ãã»ã©çå£ã«æ¢ãããšããããå€æããå¿ èŠããããã«ããŽãªãŒ0 ã¯ã çµè©äŸ¡ãäžãããã«ãã®ãããªæ¯èŒãå¿ èŠãªå Žåã«ã¯ãå€ããã£ã«ã ã®æ¯èŒ
ã«éã£ãŠäœ¿çšããã¹ãã§ããã B è©äŸ¡ãå®äºïŒ çµè©äŸ¡ã«ããŽãªãŒïŒ
ã«ããŽãªãŒ1ïŒé°æ§ïŒ ç¹èšäºé ãªããä¹³æ¿ã¯å¯Ÿç§°æ§ã§ãè «ç€ãæ§é çããã¿ãç³ç°åã®çãã¯èªããããªãã
ã«ããŽãªãŒ2ïŒè¯æ§æèŠïŒ ã«ããŽãªãŒ1 ãšåæ§ã«ããããæ£åžžãªãè©äŸ¡ã§ããããããã§ã¯ãèªåœ±è ããã³ã¢ã°ã©ãã£å ±åæžã§è¯æ§æèŠãšããè¡šçŸãéžæããŠãããéçž®ãç³ç°
åç·ç¶è ºè «ãè€æ°ã®åæ³æ§ç³ç°åãæ²¹æ§å¢èãªã©ã®èèªå«æç å€ãèèªè «ãä¹³ç€ãããã³æ··åå¯åºŠã®éèª€è «ã¯ãã¹ãŠãç¹åŸŽçã«è¯æ§ã®æ§çžã瀺ããé
éãããããšã¯ã»ãšãã©ãªããèªåœ±è ã¯ãä¹³æ¿å ãªã³ãç¯ãè¡ç®¡ç³ç°åãã€ã³ãã©ã³ãããŸãã¯æããã«éå»ã®æè¡ã«é¢é£ããæ§é çããã¿ããããã
ãã³ã¢ã°ã©ãã£äžã®æªæ§çŸæ£ã®åŸŽåã¯ååšããªããšçµè«ã¥ããããããšè¡šçŸããããšãããã ã«ããŽãªãŒ1 ããã³ã«ããŽãªãŒ2 ã®è©äŸ¡ã¯ãšãã«ããã³ã¢ã°ã©ãã£äžã®æªæ§çŸæ£ã®åŸŽåã¯ååšããªãããšã瀺ããŠããç¹ã«æ³šæããã®çžéã¯ã1 ã€ãŸ
ãã¯è€æ°ã®ç¹ç°çè¯æ§ãã³ã¢ã°ã©ãã£æèŠãå ±åæžã«èšèŒããå Žåã«ã¯ã«ããŽãªãŒ2 ãçšããèšèŒããæèŠãç¹ã«ååšããªãå Žåã«ã¯ã«ããŽãªãŒ1 ãçšããç¹ã«ããã
1 ãã³ã¢ã°ã©ãã£çµæã¯å¿ ã çµè©äŸ¡ã«ããŽãªãŒã䜿ã£ãŠå ±åããªããã°ãªããªãïŒãã³ã¢ã°ã©ãã£å質åºæºæ³ã çµèŠåãå®å ±62(208):55988, 1977ïŒ 2 ãã®è¡šã®çšèªã¯ã¢ã¡ãªã«æŸå°ç·åŠäŒïŒACRïŒã«åŸã£ãŠãããACR Breast Imaging Reporting and Data System, Breast Imaging Atlas. Reston VA. American College of Radiology, 2003
æèŒã®ACR-BI-RADS® - ãã³ã¢ã°ã©ãã£ç¬¬4 çã詳ããã¯www.acr.org ãåç §ã ãã¢ã¡ãªã«æŸå°ç·åŠäŒã®èš±å¯ãåŸãŠè»¢èŒããã®ææžã®ä»ã®æåã§ãã¢ã¡ãªã«æŸå°ç·åŠäŒããã®æžé¢ã«ãã蚱諟衚åºãªãã«äœ¿çšæš©éãäžããããŠãããã®ã¯ãªããã
ãã³ã¢ã°ã©ãã£è©äŸ¡ ã«ããŽãªãŒã®å®çŸ© ïŒ2 é äžã® 2ïŒãåç §
Guidelines Index Breast Screening TOC
MS, References
BSCR-C 2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã 2 ã® 2
泚æïŒç¹ã«æå®ã®ãªãéããæšå¥šäºé ã¯å šãŠã«ããŽãªãŒ2A ã§ããã èšåºè©ŠéšïŒNCCN ã¯ããã¹ãŠã®çæ£è ã«å¯Ÿãã è¯ã®ç®¡çæ³ã¯èšåºè©Šéšã«ãããšèããŠãããèšåºè©Šéšãžã®åå ãç¹ã«å§ããããã
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ãã³ã¢ã°ã©ãã£è©äŸ¡ã«ããŽãªãŒã®å®çŸ© 1,2 ïŒç¶ãïŒ
ã«ããŽãªãŒ3ïŒããããè¯æ§æèŠïŒçæéåŸã®è¿œè·¡ãå§ããããïŒ ãã®ã«ããŽãªãŒã«å«ãŸããæèŠã¯æªæ§çŸæ£ã®ãªã¹ã¯ã 2ïŒ æªæºã®ãã®ã§ããã远跡æéãçµãŠãå€åãèµ·ãããšã¯æãããªãããããããæŸå°ç·ç§å»ã¯ãã
ãå€ãããªãããšãæããšèããããã ç¹å®ã®ãã³ã¢ã°ã©ãã£æèŠã«ã€ã㊠åã®çæéã®è¿œè·¡ã®å®å šæ§ãšæå¹æ§ãå®èšŒããååãèšåºè©Šéšãããã€ãååšããã 3 ã€ã®ç¹å®æèŠãããããè¯æ§ãšèšèŒãããïŒç³ç°åããŠããªãè «ç€ãçŠç¹æ§ã®é察称ãããã³äžžãïŒç¹ç¶ã®ïŒç³ç°åïŒåŸè ã¯äžéšã®æŸå°ç·ç§å»ãçµéšç
ã«çµ¶å¯Ÿçè¯æ§ç¹åŸŽãšã¿ãªããŠãããã®ã§ããïŒãçºè¡šãããŠããç 究ã®ãã¹ãŠããããããè¯æ§ïŒã«ããŽãªãŒ3ïŒãšããè©äŸ¡ãäžãåã«å®å šãªç»å蚺ææ€æ»
ãå®æœããå¿ èŠãããããšã匷調ããŠããããããã£ãŠãã¹ã¯ãªãŒãã³ã°æ€æ»ã®è§£éã§ãã®ãããªè©äŸ¡ãäžãããšã¯å§ããããªãããŸããçºè¡šãããŠãã
ç 究ã®ãã¹ãŠã觊ç¥å¯èœç å€ãé€å€ããŠããããã觊ç¥å¯èœç å€ã«ããããè¯æ§ãšããè©äŸ¡ã䜿çšããããšã¯ç§åŠçããŒã¿ã«è£ä»ããããŠããªããããã«
ãŸããçºè¡šãããŠãããã¹ãŠã®ç 究ããã®ãšããã³ã¹ã¯ãããããè¯æ§ãšè©äŸ¡ããç å€ã®å€§ãããç¯å²ãå¢å€§ãããšãã«ã¯ã远跡ãç¶ãããããçæ€ãè¡
ãå¿ èŠãããããšã瀺ããŠããã ãã®ã«ããŽãªãŒã«å«ãŸããæèŠã®å€§å€æ°ã¯ãæ¯èŒçé·æéïŒ2 幎以äžïŒã®å€§ãããå®èšŒããããŸã§ã åã®çæéåŸã®è¿œè·¡ïŒ6 ã«æåŸïŒæ€æ»ãšãã®åŸã®è¿œ
å æ€æ»ã«ãã£ãŠç®¡çãããããçæ€ãå®æœãããå ŽåãããïŒæ£è ã®åžæãŸãã¯èšåºçé¢å¿ã«ããïŒã
ã«ããŽãªãŒ4ïŒç°åžžãçãããïŒçæ€ãèæ ®ããã¹ãã§ããïŒ ãã®ã«ããŽãªãŒã¯ãå žåçãªæªæ§æ§çžã¯ç€ºããŠããªããã«ããŽãªãŒ3 ãäžåãåºç¯ãªæªæ§å¯èœæ§ãèªããããæèŠã«çšããããããã®ãããä¹³æ¿çæ€ãå§
ããããæèŠã®å€§éšåããã®ã«ããŽãªãŒã«å«ãŸãããæ£è ãšãã®äž»æ²»å»ã çµçè¡åæ¹éã«ã€ããŠååãªæ å ±ã«åºã¥ã決å®ãäžãããããé¢é£ããå¯èœæ§
ã瀺ãããšãå§ããããã
ã«ããŽãªãŒ5ïŒæªæ§çŸæ£ãé«åºŠã«ç€ºåãããïŒé©åãªæªçœ®ãè¬ããã¹ãã§ããïŒ ãã®ç å€ã¯çã§ããå¯èœæ§ãé«ãïŒ95ïŒ ä»¥äžïŒããã®ã«ããŽãªãŒã«ã¯ãäºåççæ€ãªãã«äžæ®µéã®å€ç§çæ²»çãèæ ®ã§ããç å€ãå«ãŸããããã ããçŸåšã®
è «ç管çã§ã¯ãããšãã°ã»ã³ããã«ãªã³ãç¯ã®ç»å蚺æãå€ç§çæ²»çã«å«ããå Žåã åã«è¡åååŠçæ³ãæäžããå Žåãªã©ãããããçµç®ççµç¹ãµã³ã
ã«æ¡åãå¿ èŠãšãããã
ã«ããŽãªãŒ6ïŒæªæ§çŸæ£ãçæ€ã§èšŒææžã¿ïŒé©åãªæªçœ®ãè¬ããã¹ãã§ããïŒ ãã®ã«ããŽãªãŒã¯ãç»å蚺æã§ç¢ºèªããã決å®çæ²»çã®åã«æªæ§çŸæ£ãçæ€ã§èšŒæãããç å€ã«çšããããã 1 ãã³ã¢ã°ã©ãã£çµæã¯å¿ ã çµè©äŸ¡ã«ããŽãªãŒã䜿ã£ãŠå ±åããªããã°ãªããªãïŒãã³ã¢ã°ã©ãã£å質åºæºæ³ã çµèŠåãå®å ±62(208):55988, 1977ïŒ 2 ãã®è¡šã®çšèªã¯ã¢ã¡ãªã«æŸå°ç·åŠäŒïŒACRïŒã«åŸã£ãŠãããACR Breast Imaging Reporting and Data System, Breast Imaging Atlas. Reston VA. American College of Radiology, 2003
æèŒã®ACR-BI-RADS® - ãã³ã¢ã°ã©ãã£ç¬¬4 çã詳ããã¯www.acr.org/ ãåç §ã ãã¢ã¡ãªã«æŸå°ç·åŠäŒã®èš±å¯ãåŸãŠè»¢èŒããã®ææžã®ä»ã®æåã§ãã¢ã¡ãªã«æŸå°ç·åŠäŒããã®æžé¢ã«ãã蚱諟衚åºãªãã«äœ¿çšæš©éãäžããããŠãããã®ã¯ãªããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³æ¬ã¬ã€ãã©ã€ã³ã«å«ãŸããã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-1
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
解 説 ã¢ã«ãŽãªãºã ã®æŽæ°ã«åãããŠçŸåšãŸã æŽæ°äžã§ããã
NCCN ã³ã³ã»ã³ãµã¹ã«ããŽãªãŒ
ã«ããŽãªãŒ1ïŒé«ã¬ãã«ã®ãšããã³ã¹ã«åºã¥ããæšå¥šãé©åã§ãããšã
ãç¹ã§ NCCN å ã®ã³ã³ã»ã³ãµã¹ãçµ±äžããŠããã
ã«ããŽãªãŒ2AïŒèšåºçµéšãå«ãããäœãã¬ãã«ã®ãšããã³ã¹ã«åºã¥ãã
æšå¥šãé©åã§ãããšããç¹ã§NCCN å ã®ã³ã³ã»ã³ãµã¹ãçµ±äžããŠããã
ã«ããŽãªãŒ2BïŒèšåºçµéšãå«ãããäœãã¬ãã«ã®ãšããã³ã¹ã«åºã¥ãã
æšå¥šãé©åã§ãããšããç¹ã§ NCCN å ã®ã³ã³ã»ã³ãµã¹ãçµ±äžããŠããª
ãïŒãã ã倧ããªæèŠã®äžäžèŽã¯ãªãïŒã
ã«ããŽãªãŒ3ïŒæšå¥šãé©åã§ãããšããç¹ã§ NCCN å ã«å€§ããªæèŠã®äž
äžèŽãããã
ç¹ã«æå®ã®ãªãéãæšå¥šäºé ã¯ãã¹ãŠã«ããŽãªãŒ2A ã§ããã
æŠ èŠ
åè¡åœå ã®å¥³æ§ãä¹³çãçºçããç涯ãªã¹ã¯ã¯ã è¿ã® 5 幎éã§äžæã
ãŠããŠããã寿åœã 85 幎ãšãããšã7 人㫠1 人ã®å¥³æ§ããªã¹ã¯ãè² ã
ããšã«ãªãã2006 幎ã«ã¯åè¡åœã§ 214,640 äŸïŒå¥³æ§ 212,920 äŸãç·æ§
1,720 äŸïŒãæ°ãã«ä¹³çãšèšºæããã41,430 äŸïŒå¥³æ§ 40,970 äŸãç·æ§
460 äŸïŒããã®çŸæ£ã«ãã£ãŠæ»äº¡ãããšäºæ³ãããŠãã 1ããã ãæå ±ãš
ããŠã¯ãä¹³çã«ããæ»äº¡çããããã«äœäžåŸåã«ããããã®äœäžã«ã¯ãéš
åçã«ã§ã¯ãããããã³ã¢ã°ã©ãã£ã«ããã¹ã¯ãªãŒãã³ã°ãå¯äžããŠãã
ãšãããŠãã 2,3ã æ»äº¡çããã®ãŸãŸæžå°ããç¶ããããã«éèŠãªããšã¯ãè²»çšå¹æã®é«ãæ¹
æ³ã«ããæ©æçºèŠãšæ£ç¢ºãªèšºæã§ãããNational Comprehensive Cancer NetworkïŒNCCNïŒã®ä¹³çã¹ã¯ãªãŒãã³ã°ã»èšºæå§å¡äŒãäœæããå®è·µã¬
ã€ãã©ã€ã³ã¯ãèšåºã«ãããææ決å®ãä¿ãããã«äœãããŠããã
èŠè§Šèšº
ä¹³æ¿ã®ç°åžžãã¹ã¯ãªãŒãã³ã°ããŠè©äŸ¡ããããã®ãã®ã¬ã€ãã©ã€ã³ã®åºçº
ç¹ã¯èŠè§Šèšºã§ãããäžè¬å€§è¡ãšå»çé¢ä¿è ã¯ããã³ã¢ã°ã©ãã£ãç¬ç«ãã
æé ã§ã¯ãªãããšã«æ°ä»ãå¿ èŠãããããã³ã¢ã°ã©ãã£ã® æ°ãã¯ãããžãŒ
ãããã®åŸã®èªåœ±ãã誰ã«ã§ãæ±ãããããªãã®ã§ã¯ãªããé©åãªç®¡çã
確å®ãªãã®ãšããããã«ã¯ãèšåºå€æãå¿ èŠã§ãããæ£è ã®å¿é ãšèŠè§Šèšº
æèŠããX ç·ããã³çµç¹åŠçè©äŸ¡ãšãšãã«èæ ®ããªããã°ãªããªãã èŠè§ŠèšºæèŠé°æ§ã®ç¡çåæ§ã®å¥³æ§
çç¶ã®ãªã女æ§ã§èŠè§Šèšºãé°æ§ã§ãã£ãå Žåã次ã®ææ決å®ãã€ã³ãã¯ãª
ã¹ã¯ã®å±€å¥åã«ãã£ãŠæ±ºãŸããã¹ã¯ãªãŒãã³ã°æšå¥šã®ç®çããã女æ§ã¯å€§
ãã 2 ã€ã®åºæ¬çã«ããŽãªãŒãããªãã¡æ£åžžãªã¹ã¯éå£ãšé«ãªã¹ã¯éå£
ã«åãããããé«ãªã¹ã¯ã«ããŽãªãŒã¯ãïŒ1ïŒä»¥åã«æ²»ççèžéš X ç·ç §å°
ããªãã¡ãã³ãã«æŸå°ç·ç §å°ãåããããšããã女æ§ãïŒ2ïŒæµžæœ€æ§ä¹³çã®
5 幎ãªã¹ã¯ã 1.7ïŒ ä»¥äžã® 35 æ³ä»¥äžã®å¥³æ§ãïŒ3ïŒåŒ·åãªå®¶ææŽãŸãã¯éº
äŒççŽ å ã®ãã女æ§ãïŒ4ïŒäžç®å å°èçïŒLCISïŒãŸãã¯ALH(Atypical Lobular Hyperplasia)ã®å¥³æ§ãããã³ïŒ5ïŒä»¥åã«ä¹³çã®ç æŽ ã®ãã女æ§ãšãã 5 ã€ã®ã°ã«ãŒããå«ãŸããã å³å¯ã«èšããšãèªå·±æ€èšºïŒBSEïŒã¯ãããã®ãªã¹ã¯ã°ã«ãŒãã«ãããŠãä»»
æã§ãããšèããããããšããã®ããäžåœã®äžæµ·ã§å®æœããã BSE ã¹ã¯
ãªãŒãã³ã°ã®å€§èŠæš¡ãªã©ã³ãã åè©Šéšã§ã¯ãBSE ãæå°ããŠãä¹³çæ»äº¡
çã®äœæžã«å¹æããªãããšã瀺ãããŠããããã§ããããã®è©Šéšã§ã¯ã
266,064 人ã®å¥³æ§ãBSE ã®æå°ãåãã矀ãšåããªã矀ã«ã©ã³ãã ã«å²
ãä»ããããããã£ãŒãããã¯ãšåŒ·åè¬åº§ã«ãã£ãŠã³ã³ãã©ã€ã¢ã³ã¹ãä¿
ãããã10ïœ11 幎ã®è¿œè·¡æéåŸã®ä¹³çæ»äº¡äŸã¯ãæå°çŸ€ã§ 135 äŸãå¯Ÿç §
矀ã§131 äŸã§ããããã®2 矀ã®çŽ¯ç©ä¹³çæ»äº¡çã«ææå·®ã¯èªããããªãã£
ããèŠã€ãã£ãè¯æ§ã®ä¹³æ¿ç å€ã®æ°ã¯ãBSE æå°çŸ€ã®æ¹ãå¯Ÿç §çŸ€ããã
å€ãã£ã 4ãããããBSE ã«ãã£ãŠã«ãŒãã³ã®ã¹ã¯ãªãŒãã³ã°ã®åéã«ç
ãèŠã€ããããšãããããããã¯ãå§ããŠããã¹ãã§ãããå®æçãªäžè²«
ãã BSE ã«ãããä¹³æ¿ã«å¯Ÿããèªå·±èªèãé«ããããšãã§ãããéçµå
ã®å¥³æ§ã®å Žå㯠BSE ãçççµäºæã«è¡ãã®ã ãæçã§ããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-2
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
æ£åžžãªã¹ã¯ã®å¥³æ§
幎霢ã 20ïœ39 æ³ã®å¥³æ§ã«ã¯ã1ïœ3 幎ããšã®èŠè§Šèšºãšå®æç BSE ãå§
ããããã40 æ³ä»¥äžã®å¥³æ§ã«ã¯ãæ¯å¹Žã®èŠè§Šèšºãšã¹ã¯ãªãŒãã³ã°ãã³ã¢
ã°ã©ãã£ãããã³å®æç BSE ãå§ããããããã幎霢ã«ããŽãªãŒã«ãã
ãã¹ã¯ãªãŒãã³ã°ãšåœéœæ§ã«å¿ èŠãªèšºæ粟å¯æ€æ»ã®è²»çšå¹æã«ã€ããŠã¯ç°
è«ãããããã»ãšãã©ã®å»çå°é家ã¯ã¹ã¯ãªãŒãã³ã°ãã³ã¢ã°ã©ãã£ãæ¯
æããçŸåšã®å§åãæ¹ããŠæ¯èªããŠããã40 æ³ããæ¯å¹Žã®ã¹ã¯ãªãŒãã³
ã°ãå§ãããšããæšå¥šå 容ã¯ãã¢ã¡ãªã«çåŠäŒã®ã³ã³ã»ã³ãµã¹å£°æã«åºã¥
ããŠãããåœç«çç 究æãããã®æ¯èŒçè¥ã幎霢矀ã«ãããã¹ã¯ãªãŒãã³
ã°ã«ããå®éã«ä¹³çæ»äº¡çãäœäžããŠããããšã«åæããŠãã 5ã è¿ã
è€æ°ã®ç 究ããæ¯èŒçè¥ã女æ§ã«ãããçåå©çã 50 æ³ãè¶ ãã女æ§ã§
èŠããããã®ãšåçã§ããããšãå ±åãã 6ã é«ãªã¹ã¯å¥³æ§
以åã«æ²»ççèžéš X ç·ç §å°ãåããããšããã女æ§ïŒ 以åã«èžéšæŸå°ç·ç §å°ãåããããšã®ãã 25 æ³ä»¥äžã®å¥³æ§ã«ã¯ãæ¯å¹Žã®
ãã³ã¢ã°ã©ã ãš 6ïœ12ã«æããšã®èŠè§Šèšºãå§ãããããå®æçBSE ãè¡ã£
ãæ¹ãããããããã®æ£è ã§ã¯éåžžãæŸå°ç·æé²ãã 8ïœ10 幎åŸãŸãã¯
40 æ³ã«ãªã£ããšãã«ãã³ã¢ã°ã©ã ã¹ã¯ãªãŒãã³ã°ãéå§ããã25 æ³æª
æºã®å¥³æ§ã«ã¯ãæ¯å¹Žã®èŠè§Šèšºãšå®æç BSE ãå§ããããã é 延å¹æè©ŠéšçŸ€ 7 ããã®çµæã¯ãå代ãŸãã¯äºå代ã§èžéšæŸå°ç·ç §å°ãå
ãã女æ§ã§ã¯ã40 æ³ãŸã§ã«ä¹³çãçºçãããªã¹ã¯ã 35ïŒ ã§ããããšã瀺
ããŠãããè¥éœ¢æã®èžéšæŸå°ç·ç §å°ã«é¢é£ããå šäœçãªã¹ã¯ã¯ãäžè¬éå£
ã®ä¹³çãªã¹ã¯ã® 75 åãšãªããè¥ã女æ§ã«ããããã³ã¢ã°ã©ãã£ã«ãã环
ç©æŸå°ç·æé²ãã®ãã®ãçã®ãªã¹ã¯ããããããšããå¿é ããããããã®
é«ãªã¹ã¯çŸ€ã§ã¯ä¹³çãæ©æã«çºèŠããå©çã®æ¹ãå¯äœçšã®å±éºæ§ããã倧
ãã 8ã 浞最æ§ä¹³çã® 5 幎ãªã¹ã¯ã 1.7ïŒ ä»¥äžã® 35 æ³ä»¥äžã®å¥³æ§ïŒ 35 æ³ä»¥äžã®å¥³æ§ã«ã¯ãé«ãªã¹ã¯éå£ãç¹å®ããããã®ãªã¹ã¯è©äŸ¡ããŒã«
ãçšæãããŠãããåœç«çç 究æããä¹³çã®å±éºå åã®æ°ã«ãã£ãŠå¥³æ§ã«
æ£ç¢ºãªãªã¹ã¯æå°ãè¡ãä¿®æ£ Gail ã¢ãã« 9 ã«åºã¥ããã³ã³ãã¥ãŒã¿åãª
ã¹ã¯è©äŸ¡ããŒã«ãéçºããŠãããä¿®æ£ Gail ã¢ãã«ã§ã¯ã幎霢ãå朮ãå
çç£ã®å¹Žéœ¢ãŸãã¯æªçµç£ãä¹³çã®äžç芪è¡çžè ã®æ°ã以åã®è¯æ§ä¹³æ¿çæ€
çµæã®åæ°ã以åã®ä¹³æ¿çæ€ã§ã® ALHãããã³äººçš®ã®é¢æ°ãšããŠæµžæœ€æ§
ä¹³çã®ãªã¹ã¯ãè©äŸ¡ããããã®ããŒã«ã¯ã5 幎ããã³ç涯ã«æå°ãã浞最
æ§ä¹³ççºç確çãèšç®ããŠå°å·ããŠããããããé«ãªã¹ã¯å¥³æ§ãç¹å®ãã
ãã«å©çšããããšãã§ããããã ããçœäººä»¥å€ã®å¥³æ§ã§ã¯ãGail ã¢ãã«
ã§ä¹³çãªã¹ã¯ãæ£ç¢ºã«è©äŸ¡ã§ããªãããšãããã ä¹³ççºçãªã¹ã¯ã®å¢å€§ã¯ã1.7ïŒ ä»¥äžã® 5 幎ãªã¹ã¯ãšå®çŸ©ããããããã¯ã
ç±³åœã§ä¹³çã蚺æããã人ã®å¹Žéœ¢äžå€®å€ã§ãã60 æ³ã®å¥³æ§ã®å¹³åãªã¹ã¯
ã§ãããã¿ã¢ãã·ãã§ã³ãšãã©ã»ããæ¯èŒããå šåœå€ç§çã¢ãžã¥ãã³ãä¹³
æ¿ã»è žãããžã§ã¯ãïŒNSABPïŒäºé²è©Šéšãšã¿ã¢ã ã·ãã§ã³ã»ã©ããã·ãã§
ã³ è©ŠéšïŒSTARïŒã§ã¯ãä¹³çã® 5 幎äºæž¬ãªã¹ã¯ã 1.7ïŒ ä»¥äžã§ããããšã
åå èŠä»¶ãšãããã åœç«çç 究æãšå šåœå€ç§çã¢ãžã¥ãã³ãä¹³æ¿ã»è žãããžã§ã¯ãïŒNSABPïŒã®çç©çµ±èšåŠã»ã³ã¿ãŒã¯å¥³æ§ã®æµžæœ€æ§ä¹³çã®ãªã¹ã¯ã枬å®ããããã®åæ¹
åããŒã«ãéçºããhttp://bcra.nci.nih.gov/brc/ã§å ¬éããŠããã ãªã¹ã¯ã 1.7ïŒ ä»¥äžã§ 35 æ³ä»¥äžã®å¥³æ§ã«ã¯ã6ïœ12 ã«æããšã®èŠè§Šèšºãš
æ¯å¹Žã®ãã³ã¢ã°ã©ãã£ãããã³å®æçBSE ãå§ããããããŸãããã®ã°
ã«ãŒãã®å¥³æ§ã«ã¯NCCNä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ã«åŸã£ããªã¹ã¯äœæž
æŠç¥ã®èæ ®ãèŠè«ããã¹ãã§ããã 匷åãªå®¶ææŽãŸãã¯éºäŒççŽ å ã®ãã女æ§ïŒéºäŒççŽ å ã¯ãæ£è ãéºäŒ
åæ€æ»ã«çŽ¹ä»ããããã«çšããããŠãã家ææŽã«ãã£ãŠå®çŸ©ããããç°åžž
ã«æ©æã«ä¹³çãçºçãã家æã®ããæ¯èŒçå°äººæ°ã®å®¶åºãç¹ã«ç·æ§ä¹³çæ£
è ããã家åºã®å¥³æ§ãéºäŒçãªã¹ã¯ããããšã¿ãªãã¹ãã§ããã ã¢ã¡ãªã«èšåºè «çåŠäŒïŒASCOïŒãçå®ããéºäŒççŽ å ïŒBRCA 1 çªç¶å€
ç°ïŒã®åºæº 10 ã¯æ¬¡ã®ãšããã§ããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-3
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
幎霢ã«ãããããä¹³çæ£è ã 2 人以äžãåµå·£çæ£è ã 1 人以äžãã家
åº 50 æ³ãŸã§ã«ä¹³çã蚺æããã家æã 4 人以äžããå®¶åº ä¹³ç 2 åãåµå·£ç 2 åããŸãã¯ä¹³çãšåµå·£çã®ããããã®çµã¿åãã
ã 50 æ³ãŸã§ã«èšºæãããå§åŠ¹ãããå®¶åº ASCO ã¯ãçæåæ§ã«é¢ããéºäŒåæ€æ»ã«ã€ããŠã® 2003 幎ã®æŽæ°å£°æ
ã§ã次ã®ãããªéºäŒåæ€æ»é©å¿çãæ¿èªãã 11ãããªãã¡ïŒiïŒéºäŒççæ
åæ§ã瀺åããå人æŽãŸãã¯å®¶ææŽãïŒiiïŒæ€æ»ãé©åã«è§£éã§ããããšã
ããã³ïŒiiiïŒçµæãçã®éºäŒçãªã¹ã¯ããã€æ£è ãŸãã¯å®¶æã®èšºæã«åœ¹ç«
ã€ããå ç§çãŸãã¯å€ç§ç管çã«åœ±é¿ããããšã éºäŒæ§ã®ä¹³çããã³åµå·£çïŒHBOCïŒã®éºäŒççŽ å ã®ãã女æ§ã¯ã25 æ³ãã6ïœ12 ã«æããšã®èŠè§Šèšºãšæ¯å¹Žã®ãã³ã¢ã°ã©ã ãåããã¹ãã§ããã
ä¹³çã®åŒ·åãªå®¶ææŽãŸãã¯ãã®ä»ã®éºäŒççŽ å ããã€25 æ³ä»¥äžã®å¥³æ§ã¯ã
家æ㮠幎å°ã®ä¹³çæ£è ã®çºç幎霢ãã 5ïœ10 幎æ©ãã6ïœ12 ã«æããš
ã®èŠè§Šèšºãšæ¯å¹Žã®ãã³ã¢ã°ã©ã ãåãå§ããã¹ãã§ãããå®æçBSE ãå§ããããããã³ã¢ã°ã©ã ãšèŠè§Šèšºã®è£å©ãšããŠãæ¯å¹Žã®MRIïŒç£æ°å ±é³Ž
ç»åæ³ïŒãå§ãããããä¹³çã®åŒ·åãªå®¶ææŽãŸãã¯ãã®ä»ã®éºäŒççŽ å ã
ã〠25 æ³æªæºã®å¥³æ§ã¯ãæ¯å¹Žã®èŠè§Šèšºãåããå®æçBSE ãå®æœãã
ããšãå§ããããããã®ã°ã«ãŒãã®å¥³æ§ã«ã¯ãNCCN ä¹³çãªã¹ã¯äœæžã¬
ã€ãã©ã€ã³ã«åŸã£ããªã¹ã¯äœæžæŠç¥ãèæ ®ããæ©äŒãæäŸããå¿ èŠãããã éºäŒçççŽ å ããã€è¥ã女æ§ã«ããããã³ã¢ã°ã©ãã£ã«ããæŸå°ç·æé²ã
ãã®ãªã¹ã¯ã¯äžæã§ããããã®éºäŒçå åãæŸå°ç·ç §å°ã«å¯Ÿããæåæ§ã
é«ãåŸããšããå¿é ããããããããBRCA 1 çªç¶å€ç°ããã€å¥³æ§ã®40 æ³ãŸã§ã®ä¹³çã®çŽ¯ç©ãªã¹ã¯ã¯19ïŒ ãšããé«å€ã§ãã 12ãBRCA 1 ãŸãã¯BRCA 2 çªç¶å€ç°ãã£ãªã¢ã«ãããä¹³çã®å šäœçãªã¹ã¯ã¯äžè¬éå£ã®20 åã§ã
ããããã¹ã¯ãªãŒãã³ã°ã®å©çã«ãã£ãŠãã®æŸå°ç·æé²ãæ£åœåããããš
ãã§ããã äžç®å å°èçïŒLCISïŒãŸã㯠ALH ã®å¥³æ§ïŒLCIS ãã®ãã®ã¯çã®çºçéš
äœã«ãªããªããšèããããŠããããããããããšã以åŸã«ã©ã¡ããã®ä¹³æ¿
ã«çãçºçããçžå¯Ÿå±éºåºŠã 8ïœ10 åã«äžæãããALH ãç çæèŠçã«
蚺æããããšãä¹³ççºçã®çžå¯Ÿå±éºåºŠã 4ïœ5 åã«äžæãããLCIS ãŸã
㯠ALH ããã女æ§ã«ã¯ãæ¯å¹Žã®ãã³ã¢ã°ã©ã ãš 6ïœ12 ã«æããšã®èŠè§Šèšº
ãå§ãããããå®æçèªå·±æ€èšºãè¡ãã¹ãã§ããããããã®å¥³æ§ã«ã¯ã
NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ã«åŸã£ããªã¹ã¯äœæžæŠç¥ã®èæ ® ãèŠ
è«ããå¿ èŠãããã 以åã«ä¹³çã®ç æŽã®ãã女æ§ã¯ãNCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ã®èª¿æ»ã»
远跡ã»ã¯ã·ã§ã³ã«åŸã£ãŠæ²»çãè¡ãã ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ã®èæ ®ç¹
ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ã«é¢ããèšåºè©Šéšã®å€§éšåã¯ã«ãããªã幎霢ã65 ãŸã㯠70 æ³ã«èšå®ããŠãããããé«éœ¢å¥³æ§ã®ã¹ã¯ãªãŒãã³ã°ã«é¢ããããŒ
ã¿ã¯éãããŠãããé«éœ¢è éå£ã§ã¯ä¹³çã®çºççãé«ãããšããã40 æ³ä»¥äžã®å¥³æ§ã«çšãããããã®ãšåãã¹ã¯ãªãŒãã³ã°ã¬ã€ãã©ã€ã³ãå§ãã
ãããèšåºå»ã¯åžžã«ãã¹ã¯ãªãŒãã³ã°ã¬ã€ãã©ã€ã³ãé©çšããææãå€æ
ããªããã°ãªããªããæ£è ã«å¯¿åœãå¶éãããããªé床ã®å䜵ç æ ãããã
ã¹ã¯ãªãŒãã³ã°æèŠã«åºã¥ããä»å ¥æ³ã®éå§ãèŠèŸŒãŸããªãå Žåã¯ãã¹ã¯
ãªãŒãã³ã°ãå®æœããã¹ãã§ã¯ãªãã 第äºã®èæ ®ç¹ã¯ã40ïœ49 æ³ã®å¥³æ§ã«ãããã¹ã¯ãªãŒãã³ã°ã®ééã§ããã
ä¹³çã¹ã¯ãªãŒãã³ã°ã®å©çã«ã€ããŠã¯ã¢ã¡ãªã«çåŠäŒãšåœç«çç 究æã®èŠ
解ãäžèŽããŠããããã¹ã¯ãªãŒãã³ã°ã®ééã«ã€ããŠã¯ããã³ã¢ã°ã©ã ã
æ¯å¹Žå®æœããã¹ãã 1ïœ2 幎ããšã§ããããšããç¹ã«è«äºãããããã³ã¢
ã°ã©ã ã§ã¯èŠè§Šèšºã§ç å€ãæ€åºããã 2 幎åã«ç å€ãçºèŠã§ããããšã
å€ããããNCCN ä¹³çã¹ã¯ãªãŒãã³ã°ã»èšºæã¬ã€ãã©ã€ã³å§å¡äŒã¯æ¯å¹Ž
ã®ãã³ã¢ã°ã©ãã£ãšããã¢ã¡ãªã«çåŠäŒã®ã¬ã€ãã©ã€ã³ã«åŸãããšãéžæ
ãããä¹³çã«ããæ»äº¡çãäœäžãããããã«ã¯ãæ¯å¹Žã®ã¹ã¯ãªãŒãã³ã°ã®
æ¹ãããããæçã§ããã å ã«è¿°ã¹ããšãããBSE ã«ããçåå©çã¯ãŸã å®èšŒãããŠããªãããã
ããããã«ãã£ãŠã¹ã¯ãªãŒãã³ã°ã®åéã®çãçºèŠã§ããããšãããããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-4
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ãã¯ãBSEã¯å§ããŠããã¹ãã§ããã女æ§ã¯èªåã®ä¹³æ¿ã®ããšãããç¥ã£
ãŠããã¹ãã§ãããå€åãèŠã€ãããå³åº§ã«äž»æ²»å»ã«å ±åããªããã°ãªã
ãªããããã¯ç¹å®ã®æ£åŒãªæè²ããã°ã©ã ã§è¡ãããå¿ èŠã¯ãªã 4ãçŸåš
ã®ãšããã³ã¹ã¯ãå¹³åçãªã¹ã¯ã®å¥³æ§ã«ãããã«ãŒãã³ã®ã¹ã¯ãªãŒãã³ã°
æé ãšããŠä¹³æ¿ã·ã³ãã°ã©ãã£ïŒããšãã°ã»ã¹ã¿ããã¹ãã£ã³ïŒã乳管æŽ
æµãããã㯠MRI ãå®æœããããšãæ¯æããŠããªããé«ãªã¹ã¯å¥³æ§ãŸã
ã¯ä¹³æ¿çµç¹ãçš å¯ãªå¥³æ§ã®ãã³ã¢ã°ã©ãã£ã®è£å©ãšããŠã®ä¹³çã¹ã¯ãªãŒã
ã³ã°ã®ããã® MRI ãè¶ é³æ³¢ã®äœ¿çšãæ¯æããããŒã¿ã¯éãããŠããã ãã³ã¢ã°ã©ãã£è©äŸ¡
ã¹ã¯ãªãŒãã³ã°ãã³ã¢ã°ã©ãã£ã®çµæãæ£åžžã§ãã£ãå Žåã远跡ãšããŠã¯
ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãè¡ããã¹ã¯ãªãŒãã³ã°ãã³ã¢ã°ã©ãã£ã§ç°åžžæ
èŠãæããã«ãªã£ãå ŽåãæŸå°ç·ç§å»ã¯ä»¥åã®ãã³ã¢ã°ã©ã ãæ¢ãå¿ èŠã
ãããããã¯ããã³ã¢ã°ã©ãã£äžã®çããäœãç å€ã§ç¹ã«éèŠã§ããããã£
ã«ã ãæ¯èŒããŠããŸã ã¯ã£ãããšè¯æ§ãšèšããªãçãããéšåããããšã
ã«ã¯ãè¶ é³æ³¢ã䜵çšãŸãã¯äœµçšããªãã§èšºæçãã³ã¢ã°ã©ã ãå®æœããã ãã®åŸã®ææ決å®æš¹ã¯ãã¢ã¡ãªã«æŸå°ç·åŠäŒãçå®ããä¹³æ¿ç»å蚺æå ±
åã»ããŒã¿ã·ã¹ãã ïŒBI-RADS®ïŒã«åºã¥ãããã®ãšãªã 13ãçŸåšã¯è©äŸ¡
ã«ããŽãªãŒå®çŸ©ãšåŒã°ããŠãã BI-RADS®ã®ç®çã¯ãåã«ããŽãªãŒã«é¢é£
ããæšå¥šäºé ãšãšãã«ãã³ã¢ã°ã©ãã£çµæãå ±åããããã®çµ±äžãããã·
ã¹ãã ãäœãåºãããšã§ããããã®ã¬ã€ãã©ã€ã³ã§ã¯ BI-RADS®ã®ç¬¬ 4 çãæ¡çšããŠããããã®çã§ã¯ããªãã®å€æŽãè¡ãããã«ããŽãªãŒ6 ãè¿œå
ãããŠããã BI-RADS®è©äŸ¡ã¯ãæªäºïŒã«ããŽãªãŒ0ïŒãšè©äŸ¡ã«ããŽãªãŒïŒã«ããŽãªãŒ1ã2ã3ã4ã5ã6ïŒã«åããããŠããããæªäºè©äŸ¡ãã¯ãä»å çè©äŸ¡ãå¿ èŠ
ãªæèŠãæãããã®ã«ããŽãªãŒã¯ã»ãšãã©åžžã«ã¹ã¯ãªãŒãã³ã°ç¶æ³ã§çšã
ããããäžå®ã®ç¶æ³ã§ã¯ãå®å šãªãã³ã¢ã°ã©ãã£ç²Ÿå¯æ€ æ»ã®åŸã«ãã®ã«
ããŽãªãŒã çšããããããšããããè¿œå ç»å蚺æè©äŸ¡ã®æšå¥šã«ã¯ãã¹ãã
ãå§è¿«ãæ¡å€§ãç¹æ®ãã³ã¢ã°ã©ãã£åããã³è¶ é³æ³¢ãå«ãŸããããããã
ã«éããªããæ€æ»ãé°æ§ã§ãªããå žåçãªè¯æ§æèŠãå«ãŸããŠããªãå Žå
ã«ã¯ãå¯èœãªéããçŸåšã®æ€æ»ãšéå»ã®æ€æ»ãæ¯èŒãããæŸå°ç·ç§å»ã¯ã
以åã®æ€æ»ãã©ãã»ã©çå£ã«æ¢ãããšããããå€æããå¿ èŠãããã ãã³ã¢ã°ã©ãã£è©äŸ¡ãå®äºããã°ã以äžã® 6 ã€ã® BI-RADS®ã«ããŽãªãŒã®
ããããã«ç°åžžãåé¡ããã 1ïŒé°æ§ïŒããã¯é°æ§ãã³ã¢ã°ã©ã ã§ãããä¹³æ¿ã¯å¯Ÿç§°æ§ã§ãè «ç€ãæ§é
çããã¿ãç³ç°åã®çãã¯èªããããªããããšãã°ãã¹ã¯ãªãŒãã³ã°ãã³
ã¢ã°ã©ã ã§ç°åžžãçãããå°ããªéšåãèŠã€ãã£ãããã¹ãããå§è¿«åã
å®æœããŠã¿ããšãå®å šã«æ£åžžã§èšåºçå¿é ã®ãªãæèŠãšã¿ãªããããããª
å Žåã§ããã 2ïŒè¯æ§æèŠïŒãããé°æ§ãã³ã¢ã°ã©ã ã§ãããããã®å Žåã«ã¯è¯æ§ã®æ
èŠãå®åšãããå žåçãªçäŸã·ããªãªãšããŠã¯ãç³ç°åç·ç¶è ºè «ãæ²¹æ§å¢
èããããã¯èèªè «ãªã©ã®è¯æ§ã®æ§çžã瀺ããŠããç³ç°åãæããããã
èªåœ±è ã¯ãä¹³æ¿å ãªã³ãç¯ãè¡ç®¡ç³ç°åãã€ã³ãã©ã³ãããŸãã¯æããã«
éå»ã®æè¡ã«é¢é£ããæ§é çããã¿ããããããã³ã¢ã°ã©ãã£äžã®æªæ§çŸ
æ£ã®åŸŽåã¯ååšããªããšçµè«ã¥ããããããšè¡šçŸããããšãããã 3ïŒããããè¯æ§æèŠïŒçæéåŸã®è¿œè·¡ãå§ããããïŒããã¯éåžžè¯æ§ã®
ãã³ã¢ã°ã©ã ã§ããããã®æèŠã«ã¯ãå®å®æ§ã確èªããããã®ç¶¿å¯ãªã¢ã
ã¿ãªã³ã°ãå§ãããããæªæ§çŸæ£ã®ãªã¹ã¯ã¯ 2ïŒ æªæºãšæšå®ãããã 4ïŒç°åžžãçãããïŒã³ã¢éçæ€ãèæ ®ããã¹ãã§ããïŒãã®ç å€ã¯ãåº
ç¯ãªæªæ§å¯èœæ§ãèªãããããããã³ã¢ã°ã©ãã£çã«æããã«æªæ§ã§ãã
ãšã¯èšããªããšããã«ããŽãªãŒã«å«ãŸãããæªæ§ãªã¹ã¯ã¯éåžžã«å€æ§ã§ã
ããã«ããŽãªãŒ3 ãã倧ãããã«ããŽãªãŒ5 ããå°ãããšããç¯å²ã§ããã 5ïŒæªæ§çŸæ£ãé«åºŠã«ç€ºåãããïŒãã®ç å€ã¯çã§ããå¯èœæ§ãé«ãïŒ95ïŒ ïŒã
ããã«ã¯ãæŸå°ç¶ã®è «ç€ãæªæ§æ§çžã瀺ããå€åœ¢æ§ç³ç°åãªã©ãå«ãŸããã 6ïŒæªæ§çŸæ£ãçæ€ã§èšŒææžã¿ïŒãã®ã«ããŽãªãŒã¯ãç»å蚺ææ€æ»ã§èŠã€
ãã£ãä¹³æ¿ç å€ã§ãçæ€ã§æªæ§çŸæ£ã蚌æãããŠããã決å®çæ²»çã¯ãŸã
è¡ãããŠããªããã®ãæãããã«ãä»åã®çã§è¿œå ãããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-5
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ãã³ã¢ã°ã©ã ãå®å šã«æ£åžžã§ãããããã³ã¢ã°ã©ãã£äžã§æèŠãè¯æ§ã§ã
ãã«ããŽãªãŒ1 ããã³ 2 ã«ã¯ã1 幎åŸã®ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ãã³ã¢
ã°ã©ãã£ãå§ããããã ã«ããŽãªãŒ3ïŒããããè¯æ§ïŒã§ã¯ã6 ã«æåŸãšãã®åŸã¯ 6ïœ12 ã«æããš
ã« 1ïœ2幎éã蚺æçãã³ã¢ã°ã©ã ãå®æœããã®ãé©åã§ããã åã® 6 ã«æç®ã®è¿œè·¡ã§ã¯ãææšä¹³æ¿ã®çåŽãã³ã¢ã°ã©ã ãå®æœããã12 ã«æç®ã®
æ€æ»ã§ã¯ãæ¯å¹Žãšããé©åãªééã§å¯ŸåŽã®ä¹³æ¿ã®ç»åãåŸãããããã40 æ³ä»¥äžã®å¥³æ§ã«ã¯äž¡åŽã®æ€æ»ãè¡ãããã®åŸã®è¿œè·¡ã¯ãæžå¿µã®ã¬ãã«ã«å¿
ããŠäž¡åŽã«æ¯å¹ŽãŸãã¯åé¡ã®ä¹³æ¿ã«6 ã«æããšã«ãã³ã¢ã°ã©ã ãå®æœãã
åèš 2 幎éç¶ããã ãã³ã¢ã°ã©ãã£äžã§ç å€ãå®å®ãããŸãŸã§ãã£ããæ¶å€±ãããããå Žåã¯ã
åã³ã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã®ééã§ãã³ã¢ã°ã©ãã£ãå®æœãããéäžã®
ãã³ã¢ã°ã©ã ã§ç å€ã®å¢å€§ãè¯æ§ç¹åŸŽã®å€åãèŠãããå Žåã¯ãçæ€ãå®
æœããããã®çæ远跡ã¢ãããŒãã®äŸå€ã¯ãåæ¥é¢ã確å®ã§ãªãå Žåãæ£
è ã®äžå®ã倧ããå Žåããããã¯ä¹³çã®åŒ·åãªå®¶ææŽããã å Žåã§ããã
ãã®ãããªå Ž åã«ã¯ãçµç¹åŠçãµã³ããªã³ã°ãè¡ãçæ€ã åã«å®æœã
ãã®ã劥åœãªéžæè¢ãšãªãã ã«ããŽãªãŒ4 ããã³ 5 ã§ã¯ãã³ã¢éçæ€ïŒæãŸããïŒãŸãã¯ããã¯ã¯ã€
ã€ãŒæ¿å ¥äžåé€çæ€ã«ããçµç¹èšºæãšæšæ¬ X ç·åçãå¿ èŠã§ãããéç
æ€ïŒç©¿åºåžåŒçŽ°è蚺ãŸãã¯ã³ã¢éçæ€ïŒãè¡ãå Žåã¯ãç çå ±åãšç»å蚺
ææèŠãäžèŽããŠããªããã°ãªããªã 14,15ãããšãã°ãæŸå°ç¶ã®ã«ããŽãªãŒ
5 ã®è «ç€ã®çŽ°éåžåŒçµæãé°æ§ãšããã®ã¯äžäžèŽã§ãããæããã«åãå ¥
ããããšã®ã§ããªã蚺æã§ãããç çæ€æ»ãšç»å蚺ææ€æ»ãäžäžèŽã®å Žå
ã¯ãä¹³æ¿ç»å蚺æãåå®æœããè¿œå ã®çµç¹ãæ¡åãŸãã¯åé€ããã ã«ããŽãªãŒ6ïŒæªæ§çŸæ£ã蚌ææžã¿ïŒã§ã¯ãæ£è ã NCCN ä¹³çæ²»çã¬ã€
ãã©ã€ã³ã«åŸã£ãŠç®¡çããå¿ èŠããããç çæ€æ»ãè¯æ§ã§ããã³ã¢ã°ã©ã
ã§çããããªã¹ã¯ãšäžèŽããŠããå Žåã¯ãæ£è ããã³ã¢ã°ã©ãã£ã§è¿œè·¡ãã
æœèšã®å¥œã¿ã«ãã£ãŠ6ïœ12ã«æåŸã«æ°ããªããŒã¹ã©ã€ã³ãã³ã¢ã°ã©ã ãå®
æœããããæ£è ãã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã«åŸ©åž°ããããããããALHã
LCISãæŸå°ç¶ç¢çãªã©ã®è¯æ§çµç¹ç ççµæãã³ã¢éçæ€ã§èšºæãããå Ž
åã¯ãåé€çæ€ãå¿ èŠã§ããããšããã®ãããããã®ç å€ã¯æªæ§éçšã«é¢
ä¿ããŠããå ŽåãããããŸãè¯æ§ãšãã蚺æããµã³ããªã³ã°ãšã©ãŒã«ãã
ãã®ã§ããå¯èœæ§ãããããã§ãã 16-18ã èŠè§Šèšºã§ã®éœæ§æèŠ ä¹³æ¿å ã®äž»èŠãªè «ç€
äž»èŠãªè «ç€ãšã¯ãèŠè§Šèšºã§å®¹æã«ç¢ºèªã§ããå€ç«æ§ã®ç å€ãèšãããã®ã¬
ã€ãã©ã€ã³ã§ã¯ãäž»èŠãªè «ç€ã®è©äŸ¡ã 30 æ³ä»¥äžã®å¥³æ§ãš 30 æ³æªæºã®å¥³
æ§ãšãã 2 ã€ã®å¹Žéœ¢çŸ€ã«åããŠããã 30 æ³ä»¥äžã®å¥³æ§ïŒ30 æ³ä»¥äžã®å¥³æ§ã®äž»èŠãªè «ç€ã®è©äŸ¡ã«é¢ããã¬ã€ã
ã©ã€ã³ã®äž»ãªçžéç¹ã¯ãä¹³çã®çãã®çšåºŠã®å¢å€§ã§ããã åã®è©äŸ¡ã¯äž¡
åŽã®èšºæçãã³ã¢ã°ã©ã ããå§ããããããªãè©äŸ¡ãè¡ããªãçµé芳å¯ã¯
éžæè¢ã«å«ãŸããŠããªãããã³ã¢ã°ã©ãã£è©äŸ¡ã§åŸãããç°åžžæèŠã¯ã6 ã€ã® BI-RADS®ã«ããŽãªãŒã®ããããã«åé¡ããã BI-RADS®ã«ããŽãªãŒ1ã2 ããã³ 3 ã§ã¯ã次ã®æ®µéãšããŠè¶ é³æ³¢ãå®æœ
ãããã®æèŠã«ã€ããŠã¯ä»¥äžã§èå¯ãããBI-RADS®ã«ããŽãªãŒ4 ããã³
5 ã§ã¯ãèšåºæèŠãšç»å蚺ææèŠã®äœçœ®ççžé¢ã®è©äŸ¡ãå¿ èŠã§ãããçžé¢
ãèªããããªããã°ãBI-RADS®ã«ããŽãªãŒ1ã2 ãŸã㯠3 ãšåæ§ããã
ãªãè©äŸ¡ãè¡ããç»å蚺ææèŠã觊蚺æèŠãšçžé¢ããŠããã°ãç»åäžã®å
é¡ã®ç²Ÿå¯æ€æ»ã«ãã£ãŠè§Šèšºã§ã®åé¡ã®è§£çãåŸããããã³ã¢éçæ€ïŒæãŸ
ããïŒãŸãã¯ããã¯ã¯ã€ã€ãŒæ¿å ¥äžåé€çæ€ãšæšæ¬ X ç·åçã«ããçµç¹
蚺æãå¿ èŠã§ãããã³ã¢éçæ€ãå©çšããå Žåã¯ããã®åçš¿ã®ãã³ã¢ã°ã©
ãã£è©äŸ¡ã®ã»ã¯ã·ã§ã³ã§è¿°ã¹ããšãããç çå ±åãšç»å蚺ææèŠãäžèŽã
ãŠããªããã°ãªããªãã è¶ é³æ³¢æèŠ
è¶ é³æ³¢ã«ãã£ãŠçããããŸãã¯äžç¢ºå®ã®å å®æ§ç å€ã瀺ãããå Žåã¯ãã³
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-6
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
ã¢éçæ€ïŒæãŸããïŒãŸãã¯å€ç§çåé€ã«ãã£ãŠçµç¹çæ€ãåŸããç çæ€
æ»çµæãè¯æ§ã§ãç»åãšè¶ é³æ³¢ãäžèŽããŠããã°ãè¶ é³æ³¢ãŸãã¯ãã³ã¢ã°
ã©ã ã䜵çšãŸãã¯äœµçšããªãèŠè§Šèšºã 6ïœ12 ã«æããšã« 1ïœ2 幎éå®æœ
ããŠå€§ãããè©äŸ¡ããããšãå§ãããããèšåºçã«å¿ èŠã§ããã°ããã£ãš
çãééã§è¿œè·¡ãè¡ã£ãŠãè¯ããå å®æ§ç å€ã®å€§ãããå¢å€§ããå Žåã¯çµ
ç¹çæ€ãåå®æœãããå®å®ããç å€ã«ã¯ã«ãŒãã³ã®ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ã
è¡ããæèŠãäžç¢ºå®ãALHããããã¯è¯æ§ã§ãç»åãšäžèŽããŠããªãå Žå
ã¯ãå€ç§çåé€ãå®æœããå¿ èŠããããè¯æ§ã§ããããšã確èªãããç å€
ã«ã¯ãã«ãŒãã³ã®ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ãè¡ããç å€ãALH ãŸãã¯LCIS ãšåé¡ãããå Žåãå»åž«ã¯ NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ã«åŸã£ããª
ã¹ã¯äœæžæ²»çãèæ ®ããã¹ãã§ãããæ£è ã«ã¯å®æçãªä¹³æ¿ã¹ã¯ãªãŒãã³
ã°ãåãç¶ããããå©èšãããç å€ãæªæ§ã§ããã°ãæ£è ã NCCN ä¹³ç
æ²»çã¬ã€ãã©ã€ã³ã«åŸã£ãŠæ²»çããã è¶ é³æ³¢ã§å å®æ§ç å€ãããããè¯æ§ãšæãããå Žåã«ã¯ãå€ç§çåé€ãã³
ã¢éçæ€ïŒæãŸããïŒããããã¯èŠ³å¯ãšãã£ãããã€ãã®éžæè¢ãããã
ç å€ããã§ã«å€ç§çã«åé€ãããŠè¯æ§ã§ããããšã蚌æãããŠããå Žåã¯ã
æ£è ãã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã«åŸ©åž°ããããç å€ãALH ãŸãã¯LCIS ãšåé¡ãããå Žåãå»åž«ã¯ NCCNä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ã«åŸã£ããªã¹
ã¯äœæžæ²»çãèæ ®ããã¹ãã§ãããæ£è ã«ã¯å®æçãªä¹³æ¿ã¹ã¯ãªãŒãã³ã°
ãåãç¶ããããå©èšãããæªæ§ç å€ã¯ NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ã«
åŸã£ãŠæ²»çãããã³ã¢éçæ€ãéžæããå Žåã§ãçµæãè¯æ§ã§ç»åãšäžèŽ
ããŠãããšãã«ã¯ãè¶ é³æ³¢ãŸãã¯ãã³ã¢ã°ã©ã ã䜵çšãŸãã¯äœµçšããªãèŠ
觊蚺ã 6ïœ12 ã«æããšã« 1ïœ2 幎éå®æœããŠå€§ãããè©äŸ¡ããããšãå§
ãããããèšåºçã«å¿ èŠã§ããã°ããã£ãšçãééã§è¿œè·¡ãè¡ã£ãŠãè¯ãã
å å®æ§ç å€ã®å€§ãããå¢å€§ããå Žåã¯çµç¹çæ€ãåå®æœãããå®å®ããç
å€ã«ã¯ã«ãŒãã³ã®ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ãè¡ããç å€ãäžç¢ºå®ãALHãLCIS ãããã¯è¯æ§ã§ãç»åãšäžèŽããŠããªãå Žåã¯ãå€ç§çåé€ãå§ãããã
æ£è ã«ã¯åè¿°ã®ãšããã«å¯Ÿå¿ããã芳å¯ãéžæã§ããã®ã¯ç å€ãïŒïœïœæª
æºã§èšåºçã«æªæ§ã®çããäœãå Žåã«éããããã®å Žåã«ã¯è¶ é³æ³¢ãŸãã¯
ãã³ã¢ã°ã©ã ã䜵çšãŸãã¯äœµçšããªãèŠè§Šèšºã6 ã«æããšã«1ïœ2 幎éå®
æœããŠå®å®æ§ãè©äŸ¡ããããšãå§ããããã
è¶ é³æ³¢è©äŸ¡ã«ãã£ãŠè «ç€ãç¡çåæ§ã®åçŽå¢èãšäžèŽããããšãæããã«
ãªã£ãå Žåã«ã¯ãæ£è ãçåæ§ã§ãã£ããäžå®ããä»å ¥ãæãã ãããªã
éããå®å®æ§ã 2ïœ4 ã«æé芳å¯ããå€åãèµ·ããã°æ£è ã«å ±åããŠãã
ãããã«ããã°ååã§ãããçåæ§ãŸãã¯éåçŽå¢èãèŠã€ãã£ãå Žåã¯ã
ç©¿åºåžåŒçŽ°è蚺ãèæ ®ãããäžèŠåãªå¢èå£ãŸãã¯å¢èå ã®è «ç€ãèªãã
ããå Žåã¯ãè¶ é³æ³¢ã¬ã€ãã³ã¢çæ€ãã¯ãªããç眮ã蚺æã«åœ¹ç«ã€ããšã
ããããå€ç§çåé€ãæãŸãããç©¿åºåžåŒçŽ°è蚺ã§è¡æ¶²ãå«ãŸãªã液äœã
åŸãããè «ç€ãæ¶å€±ããå Žåã¯ãæ£è ã 2ïœ4 ã«æåŸã«åæ€æ»ãããèŠè§Š
蚺ãé°æ§ã®ãŸãŸã§ããã°ãæ£è ãã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã«åŸ©åž°ãããã
è «ç€ãåçºããå Žåã¯ãè¶ é³æ³¢ã«ãããããªãè©äŸ¡ãå¿ èŠã§ãããããã
ã¯ãå€ç§çåé€ãèæ ®ããŠãè¯ãã åã®ç©¿åºåžåŒçŽ°è蚺ã§è¡æ¶²æ§ã®æ¶²äœ
ãåŸãããããç©¿åºåžåŒçŽ°è蚺åŸã«ãè «ç€ãåç¶ããŠããããããšãã¯ã
ç»åã¬ã€ãäžçæ€ãè¡ãè¶ é³æ³¢ãå€ç§çåé€ãå¿ èŠã§ãããè¶ é³æ³¢ã§ã®ç»
åã¬ã€ãäžçæ€ã®æèŠãè¯æ§ã§ç»åãšäžèŽããŠãããšãã¯ãè¶ é³æ³¢ãŸãã¯
ãã³ã¢ã°ã©ã ã䜵çšãŸãã¯äœµçšããªãèŠè§Šèšºã6ïœ12 ã«æããšã«1ïœ2 幎éå®æœããããšãå§ãããããèšåºçã«å¿ èŠã§ããã°ããã£ãšçãééã§
远跡ãè¡ã£ãŠãè¯ããè «ç€ã®å€§ãããå¢å€§ããå Žåã¯çµç¹ãµã³ããªã³ã°ã
åå®æœããå¿ èŠãããããè «ç€ãå®å®ãããŸãŸã§ããã°ã«ãŒãã³ã®ä¹³æ¿ã¹
ã¯ãªãŒãã³ã°ãå§ãããããè¶ é³æ³¢ãšç»åã¬ã€ãäžçæ€ã®æèŠã çµçã«
è¯æ§ã§ãããç»åãäžäžèŽã§ãããäžç¢ºå®ãŸãã¯ALH ãããã¯LCIS ã§ã
ãå Žåã«ã¯ãå€ç§çåé€ãå§ãããããè «ç€ããã§ã«å€ç§çã«åé€ãããŠ
è¯æ§ã§ããããšã蚌æãããŠããå Žåã¯ãæ£è ãã«ãŒãã³ã¹ã¯ãªãŒãã³ã°
ã«åŸ©åž°ããããè «ç€ãALH ãŸãã¯LCIS ãšåé¡ãããå Žåã«ã¯ãã«ãŒãã³
ã®ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ãšãšãã«NCCN ä¹³çãªã¹ã¯äœæžã¬ã€ãã©ã€ã³ã«åŸã£
ããªã¹ã¯äœæžæ²»çãå®æœããããšãå§ãããããLCIS æèŠã®å Žå㯠äžèšã®2 ã€ã®éžæãã«å ã ãŠãæ£è ãNCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ã«åŸã£
ãŠæ²»çããå¿ èŠããããç»åã¬ã€ãäžçæ€ãè¡ã£ãè¶ é³æ³¢ãŸãã¯å€ç§çå
é€ã§æªæ§æèŠãåŸãããå Žåã¯ãNCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ã«åŸã£ã
æ²»çãæœãã ç å€ãè¶ é³æ³¢ã§èŠèŠåããããšãã§ããªãå Žåã¯ãç»å蚺ææ€æ»ã䜵çšãŸ
ãã¯äœµçšããªãçµç¹çæ€ïŒã³ã¢éçæ€ãããã¯åé€ïŒãŸãã¯èŠ³å¯ã3ïœ6 ã«æããšã« 1ïœ2 幎éå®æœãã倧ãããè©äŸ¡ãããç å€ã®å€§ãããå¢å€§ãã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-7
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
å Žåã¯çµç¹ãµã³ããªã³ã°ãåå®æœããå¿ èŠãããããç å€ãå®å®ãããŸãŸ
ã§ããã°ã«ãŒãã³ã®ä¹³æ¿ã¹ã¯ãªãŒãã³ã°ãå§ããããã 30 æ³æªæºã®å¥³æ§ïŒäž»èŠãªè «ç€ã®åæè©äŸ¡ãšããŠæãŸããéžæè¢ã¯ãè¶ é³
æ³¢ã«çŽæ¥é²ãããšã§ããããã®åŸã® 30 æ³æªæºã®å¥³æ§ã«é¢ããææ決å®æš¹
ã¯ã30 æ³ä»¥äžã®å¥³æ§ã®ãããŒãšã»ãŒåãã§ãããå¯äžã®çžéç¹ã¯ãè¥ã
女æ§ã§ã¯èšºæçãã³ã¢ã°ã©ã ãå¿ èŠã«ãªãç¶æ³ãããããšã§ãããã»ãã«
ããéçæ€ãšèŠ³å¯ãšãã 2 ã€ã®éžæè¢ãããã30 æ³æªæºã®å¥³æ§ã§ã¯çã
ã®çšåºŠãäœããããççåšæ 1ïœ2 ååã®è «ç€ã®èŠ³å¯ãšããæ¹æ³ãéžæã§
ããã芳å¯ãéžæããå Žå㧠1ïœ2 åã®ççåšæåŸã«è «ç€ãæ¶å€±ãããšã
ã¯ãæ£è ãã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã«åŸ©åž°ããããè «ç€ãåç¶ããŠããã°ã
éçæ€ãŸãã¯è¶ é³æ³¢ãå®æœãããéçæ€ã®éŸå€ã¯ã以åã®èžéšæŸå°ç·æé²ã
以åã®çæ€æèŠããããã¯ä¹³çã®å®¶ææŽã«ãã£ãŠé«ãªã¹ã¯ãšããã女æ§ã§
ã¯ãéºäŒåæ€æ»çµæã«é¢ä¿ãªãäœããšãªãã éçæ€ã®çµæã¯ã液äœãŸãã¯é液äœã® 2 çš®é¡ã§ããã液äœãåŸãããªã
ãã°ãè¶ é³æ³¢ãŸãã¯çŽ°éåžåŒïŒFNAïŒãå®æœãããè¶ é³æ³¢æèŠã¯åã«èå¯
ãããšããã«åãæ±ããFNA ãå®æœããå Žåãç çå»ã¯çŽ°èåžåŒç©ãè©
䟡ããå¿ èŠãããã现è蚺ãç·ç¶è ºè «ãšäžèŽããŠããå Žåã®å€ç§çåé€ã®
é©å¿çã¯ãæ£è ã®äžå®ã¬ãã«ãå³æã®åŠåš ã®èšç»ããããã¯è «ç€ã®å€§ãã
å¢å€§ã®ç æŽã§ãããéå¥èšºæãšããŠã¯èç¶è «çãèãããããç·ç¶è ºè «ã
2 cm æªæºã§ããã°ã1ïœ2 幎éã®èŠ³å¯ãéžæããŠãè¯ããå§ãããã芳
å¯éé㯠3ïœ6 ã«æããšã« 1ïœ2 幎éã§ããããŸããæ¯å倧ããã枬å®ã
ãŠè «ç€ã®å®å®æ§ãæ£ç¢ºã«ã¢ãã¿ãŒããç®çã§è¶ é³æ³¢ãèæ ®ããããšãå¯èœ
ã§ããã倧ããã®å¢å€§ãèŠãããå Žåã¯çµç¹ãµã³ããªã³ã°ãåå®æœããå¿
èŠãããããç å€ãå®å®ãããŸãŸã§ããã°ã«ãŒãã³ã®ä¹³æ¿ã¹ã¯ãªãŒãã³ã°
ãå§ããããã ç©¿åºåžåŒçŽ°è蚺ãé蚺æçãŸãã¯äžç¢ºå®ã®å Žåã¯è¶ é³æ³¢ãèæ ®ãããè¶ é³
æ³¢ã«ãã£ãŠäžç¢ºå®ãŸãã¯çãããå å®æ§ç å€ã瀺ãããå Žåã¯ã蚺æçã
ã³ã¢ã°ã©ã ãæ®åœ±ããã³ã¢éçæ€ãŸãã¯å€ç§ççæ€ã«ãã£ãŠãããªãçµç¹
åŠçãµã³ããªã³ã°ãå®æœããããã®åŸã¯ã30 æ³ä»¥äžã®å¥³æ§ã«é¢ããè¶ é³
æ³¢æèŠã®ã»ã¯ã·ã§ã³ã§è¿°ã¹ããšããã«è©äŸ¡ãé²ããã现è蚺ã«ãã£ãŠALH
ãæããã«ãªã£ããšãã¯ãçµç¹çæ€ã®åã«è¶ é³æ³¢ãšãã³ã¢ã°ã©ã ãå®æœã
ããçµç¹åŠçè©äŸ¡ã«ãã£ãŠçãæããã«ãªãã°ãæ£è ã NCCN ä¹³çæ²»ç
ã¬ã€ãã©ã€ã³ã«åŸã£ãŠæ²»çããã åã®ç©¿åºåžåŒçŽ°è蚺ã§éå€å·æ§ã®è¡æ¶²æ§ã®æ¶²äœãåŸãããå Žåãããã
ã¯ç©¿åºåžåŒçŽ°è蚺åŸã«ãè «ç€ãåç¶ããŠããå Žåã¯ãç»åã¬ã€ãäžçæ€ã
è¡ãè¶ é³æ³¢ãŸãã¯å€ç§çåé€ãå¿ èŠã§ããããã®åŸã®ç®¡ç㯠30 æ³ä»¥äžã®
女æ§ã®å Žåãšåæ§ã§ãããç©¿åºåžåŒçŽ°è蚺ã§è¡æ¶²ãå«ãŸãªã液äœãåŸããã
è «ç€ãæ¶å€±ããå Žåã¯ãæ£è ã 2ïœ4 ã«æåŸã«åæ€æ»ãããèŠè§Šèšºãé°æ§
ã®ãŸãŸã§ããã°ãæ£è ãã«ãŒãã³ã¹ã¯ãªãŒãã³ã°ã«åŸ©åž°ããããè «ç€ãå
ç¶ãŸãã¯åçºããå Žåã¯ãè¶ é³æ³¢ãŸãã¯å€ç§çåé€ã«ãããããªãè©äŸ¡ã
å¿ èŠã§ããã 觊ç¥å¯èœãªè «ç€ã®ãªãä¹³é åæ³
ä¹³é åæ³ãèŠãããã觊ç¥å¯èœãªè «ç€ã®ãªãæ£è ã§ã¯ãä¹³é åæ³ç©ã®ç¹åŸŽ
ã®è©äŸ¡ã第äžæ®µéãšãªããä¹³é åæ³ãäž¡åŽæ§ã§ä¹³æ±æ§ã®å Žåã¯ãåŠåš ãŸã
ã¯å åæ³æ§ã®ç å ãèæ ®ããªããã°ãªããªããä¹³æ±æ§åæ³ç©ã¯ãå粟ç¥è¬ã
æé«è¡å§è¬ããªããšãŒããçµå£é¿åŠè¬ãããã³ãšã¹ããã²ã³ã®æè¬ã§ãèŠ
ãããããšãå€ãã40 æ³æªæºã®å¥³æ§ã«ãããéèªçºçå€ä¹³ç®¡æ§åæ³ã«é©
ãã远跡ã¯èŠ³å¯ã§ãããé©åãªå Žåã«ã¯æ£è ã«ä¹³æ¿ã®å§è¿«ãæ¢ããèªçºç
åæ³ãèŠããããå ±åããããæå°ããã40 æ³ä»¥äžã®å¥³æ§ã§ã¯ãã¹ã¯ãªãŒ
ãã³ã°ãã³ã¢ã°ã©ãã£ãšBI-RADS®ã«ããŽãªãŒã«åºã¥ãããããªã粟å¯æ€
æ»ãšãšãã«ãè¥ã女æ§ãšåæ§ã®æå°ãè¡ãããšãå§ããããã ãåä»ãªä¹³é åæ³ã¯ãæç¶çãèªçºçãçåŽæ§ã挿液æ§ãè¡æ¶²æ§ããŸã
ã¯æŒ¿æ¶²è¡æ¶²æ§ã®ãã®ã§ãããä¹³é åæ³ç©ã®ã°ã¢ã€ã¯è©ŠéšãšçŽ°è蚺ã¯ä»»æã§
ãããé°æ§çµæãšãªã£ãŠããããªãè©äŸ¡ãäžæ¢ããŠã¯ãªããªãããã®çš®ã®
ä¹³é åæ³ç©ã®è©äŸ¡ã¯ã蚺æçãã³ã¢ã°ã©ã ã®BI-RADS®ã«ããŽãªãŒã«åºã¥
ããŠè¡ãã蚺æçãã³ã¢ã°ã©ã ãBI-RADS®ã«ããŽãªãŒ1ã2 ãŸã㯠3 ã§ããã°ãä»»æã§ä¹³ç®¡é 圱ãè¡ã£ãŠå€ç§çåé€ã®ã¬ã€ããšããã乳管é 圱ã
é°æ§ã§ããç°åžžãªä¹³é åæ³ã®èšºæã®ããã«ã¯ä¹³ç®¡åé€è¡ãå¿ èŠã§ãããã
ã ãã乳管é 圱ã¯å€çºæ§ç å€ã®é€å€ãè¡åã®ç å€ã®äœçœ®ç¹å®ã«ã¯æçšã§ã
ããæ£è ã®ãã³ã¢ã°ã©ã ãBI-RADS®ã«ããŽãªãŒ4 ãŸãã¯5 ã§ããå Žåã¯ã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-8
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
蚺æçãã³ã¢ã°ã©ã æèŠã«åºã¥ããŠç²Ÿå¯æ€æ»ãé²ãããæèŠãè¯æ§ãŸãã¯
äžç¢ºå®ã§ããã°ä¹³ç®¡é 圱ã¯ä»»æã§ããããå€ç§ç乳管åé€ã¯ãã¯ãå¿ èŠã§
ãããã«ããŽãªãŒ4 ãŸã㯠5 ã®ãã³ã¢ã°ã©ã ãæªæ§çŸæ£ã瀺ããŠããå Ž
åã¯ãæ£è ã NCCN ä¹³çæ²»çã¬ã€ãã©ã€ã³ã«åŸã£ãŠæ²»çããã é察称æ§é°åœ±ãŸãã¯å°çµç¯åœ¢
æé°åœ±ãå°çµç¯åœ¢æããŸãã¯é察称æ§ã¯ãæèŠããã¡ããšå®çŸ©ãããŠãã
ããä¹³æ¿èŠè§Šèšºã§ã¯ã£ããããªãããšãå€ãç¹ã§ãäž»èŠãªè «ç€ãšã¯åºå¥ã
ãããæ£è ã 30 æ³æªæºã§é«ãªã¹ã¯å åããããªãå Žåã¯ãè¶ é³æ³¢è©äŸ¡ã
é©åã§ããããã³ã¢ã°ã©ã ãå®æœãã¹ããªã®ã¯ãèŠè§ŠèšºæèŠãèšåºçã«ç
ãããå Žåã«éãããããã®å¹Žéœ¢çŸ€ã§ã¯ä¹³æ¿ã®çš å¯åºŠãšäœãä¹³çãªã¹ã¯ã«
ããã蚺æçãã³ã¢ã°ã©ã ãæçãšãªãããšãããªãå°ãªãã 30 æ³ä»¥äžã®å¥³æ§ã§ã¯ãè¶ é³æ³¢è©äŸ¡ã䜵çšãŸãã¯äœµçšããã«äž¡åŽã®èšºæç
ãã³ã¢ã°ã©ã ãæ®åœ±ãããä¹³æ¿ã®ç»å蚺æçµæãç°åžžã§ããã°ãå ã«ãã³
ã¢ã°ã©ãã£ã®ç°åžžã«ã€ããŠæŠèª¬ãããšããã«ãé°åœ±ãå°çµç¯åœ¢æãããã
ã¯é察称æ§ã«é¢ããè©äŸ¡ãå®æœããã ãã³ã¢ã°ã©ã ãšè¶ é³æ³¢ã®æèŠãæ£åžžãªããæ£è ã 3ïœ6 ã«æåŸã«åæ€æ»ã
ããæèŠãå®å®ããŠããã°ãæ¯å¹Žã®ã¹ã¯ãªãŒãã³ã°ã«åŸ©åž°ã§ããããã ãã
é²è¡ãŸãã¯èšåºççãã®å€åãèªãããããšãã¯ãäž»èŠãªè «ç€ã®å Žåãšå
æ§ã«ç²Ÿå¯æ€æ»ãé²ããã ç®èã®å€å
ä¹³æ¿åšå²ã®ç®èã®äœããã®ç°åžžãªå€åã¯æ·±å»ãªçŸæ£ã瀺ããŠããå Žåãã
ããããè©äŸ¡ãå¿ èŠã§ãããåæè©äŸ¡ã¯ãè¶ é³æ³¢æ€æ»ã䜵çšãŸãã¯äœµçšã
ãªãäž¡åŽã®èšºæçãã³ã¢ã°ã©ã ããå§ããããã³ã¢ã°ã©ã ãç°åžžã§ããã°ã
ãã®æèŠã«åºã¥ããŠè©äŸ¡ãé²ãããä¹³æ¿ã®ç»å蚺æçµæãæ£åžžã§ãã£ãŠãã
ãããªã粟å¯æ€æ»ã¯å¿ èŠã§ããã BI-RADS®ã«ããŽãªãŒ1ïœ3 ã§ã¯ãç®èã®ãã³ãçæ€ãŸãã¯ä¹³é çæ€ãå®æœ
ãããBI-RADS®ã«ããŽãªãŒ4ïœ5 ã®ãã³ã¢ã°ã©ãã£ç å€ã«ã¯ããã³ãçæ€
ã䜵çšãŸãã¯äœµçšããªãã³ã¢éçæ€ïŒæãŸããïŒãå®æœãããå€ç§çåé€
ãéžæè¢ã«å«ãŸãããç®èçæ€ãæªæ§ã§ããã°ãæ£è ã NCCN ä¹³çæ²»ç
ã¬ã€ãã©ã€ã³ã«åŸã£ãŠæ²»çããããã ããç®èçæ€ãè¯æ§ã§ãã£ãŠããç®
èã®ãã³ãçæ€ã®åå®æœãŸãã¯ä¹³é çæ€ã®å®æœïŒåã«å®æœããŠããªãå ŽåïŒ
ãå¿ èŠã§ãããä¹³æ¿å°éå»ãžã®çžè«ãèæ ®ããã¹ãã§ããã ãŸãšã
ãã®ã¬ã€ãã©ã€ã³ã¯ãå€æ§ãªä¹³æ¿ç å€ãã¹ã¯ãªãŒãã³ã°ããã³è©äŸ¡ããã
ãã®å®çšçã§äžè²«ããæ çµã¿ãå»çé¢ä¿è ã«æäŸããããšãæå³ããŠããã
æ£è ã« é©ãªç®¡çãæœãã«åœãã£ãŠã¯ãèšåºå€æãåžžã«éèŠãªæåãšãªãã ä¹³æ¿èº«äœæ€æ»ãX ç·ç»å蚺ææ³ãããã³ç çæ€æ»ã®æèŠãäžèŽããŠããªã
å Žåãèšåºå»ã¯æ£è ã®åé¡ã®è©äŸ¡ãæ éã«åèæ ®ããå¿ èŠããããå»çããŒ
ã ã®ææ決å®ã«æ£è ãå ããã°ãä¹³çãªã¹ã¯ã®ã¬ãã«ã決å®ããæš©éãæ£
è ã«äžããããšãã§ããã¹ã¯ãªãŒãã³ã°ãŸãã¯è¿œè·¡ã®å§ãã®äžã§ãããã
å人çã«åãå ¥ããŠãããããã«ãªãã ãã®ã¬ã€ãã©ã€ã³ã«ã¯ãçŸåšåãå ¥ããããŠããæ²»çã¢ãããŒãã«é¢ãã
å·çè ãã®èŠè§£ã«ã€ããŠåæãåŸããããã®ãèšããŠããããã®ã¬ã€ãã©
ã€ã³ãé©çšãããåèã«ãããããèšåºå»ã«ã¯ãåå¥ã®èšåºç¶æ³ã«ããã
ç¬ç«ããå»åŠçå€æã«ãããæ£è ã®ã±ã¢ãŸãã¯æ²»çæ³ã決å®ããŠããããš
ãæåŸ ããããNational Comprehensive Cancer Network ã¯ããã®å 容ã
䜿çšããŸãã¯é©çšã«ã€ããŠãããªãè¡šæãä¿èšŒãè¡ããã®ã§ã¯ãªãããã®
é©çšãŸãã¯äœ¿çšã«ã€ããŠãããªã責任ãè² ããªãã ãã®ã¬ã€ãã©ã€ã³ã®èäœæš©ã¯National Comprehensive Cancer Network ã«ãããNCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ããã«å«ãŸã
ãã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã©2006. NCCN ä¹³çã¹ã¯ãªãŒãã³ã°ã»èšºæã¬ã€ãã©ã€ã³å§å¡äŒã«é¢ãã æ å ±é瀺
NCCN ã¬ã€ãã©ã€ã³ãäœæããããã®å§å¡äŒäŒè°ã§ã¯ãæ¯åéå§æã«å:e
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã MS-9
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
å§å¡ããç 究æ¯æŽã顧åå§å¡äŒå§å¡ããããã¯è°é·äºåå±ãžã®åå ãšãã£
ã圢ã§åãã財æ¿çæ¯æŽã«ã€ããŠé瀺ãè¡ã£ããå§å¡äŒå§å¡ã¯ãEli Lilly 瀟㚠General Electric 瀟ããæ¯æŽãåããããšãæããã«ããã æ¥çãããŸã£ããæ¯æŽãåããŠããªãå§å¡ããããå§å¡äŒã¯ããããã®å§
å¡ã«ã€ããŠããå§å¡äŒå¯©è°ãžã®åå ãèš±å¯ã§ããªãçç±ãšãªãã»ã©ã®å©å®³
é¢ä¿ã®è¡çªã¯ååšããªããšå€æããã
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³æ¬ã¬ã€ãã©ã€ã³ã«å«ãŸããã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã REF-1
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
åèæç®
1. Jemal A, Siegel R, Ward E, et al. Cancer Statisitics, 2006. CA Cancer J Clin 2006;56:106-130..
2. Tabar L, Vitak B, Chen H-H T et al. Beyond randomized controlled trials: Organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91:1724-1731.
3. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L., Zelen M., Mandelblatt J. S., Yakovlev AY, Habbema JDF, Feuer EJ. Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators: N Engl J Med 2005;353:1784-1792.
4. Thomas DB, Gao DL, Ray RM et al. Randomized trial of breast self-examination in Shanghai: Final results. J Natl Cancer Inst 2002;94:1445-1457.
5. Joint statement on breast cancer screening for women in their 40s. The National Cancer Institute and the American Cancer Society, 1997.
6. UK Trial of Early Detection of Breast Cancer group. 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 1999;353:1909-1914.
7. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-625.
8. Aisenberg AC, Finkelstein DM, Doppke KP et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997;79:1203-1210.
9. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:
1879-1886.
10. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-1736.
11. American Society of Clinical Oncology Policy Statement Update: Genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
12. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA 1997;227:967-1003.
13. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS) Mammography, 4th Edition. Reston, Virginia: American College of Radiology, 2003.
14. Bassett L, Winchester DP, Caplan RB et al. Stereotactic coreneedle biopsy of the breast: A report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists. CA Cancer J Clin 1997;47: 171-190.
15. National Cancer Institute. Final version: the uniform approach to breast fine-needle aspiration biopsy. Breast J 1997;3:149-168.
16. Linell F. Precursor lesions of breast carcinoma. Breast 1993;2:202-223.
17. Parker SH, Burbank F, Jackman RJ et al. Percutaneous largecore breast biopsy: a multi-institutional study. Radiology 1994; 193:359-364.
18. Frouge C, Tristant H, Guinebretiere JM et al. Mammographic lesions suggestive of radial scars: Microscopic findings in 40 cases. Radiology 1995;195:623-625.
Guidelines Index Breast Screening TOC
MS, References
2007 幎第 1 çã2007 幎 1 æ 24 æ¥ãèäœæš©ææãNational Comprehensive Cancer Network, Inc. NCCN ã®æžé¢ã«ãã蚱諟ãªãæ¬ã¬ã€ãã©ã€ã³ããã³ã€ã©ã¹ããè€è£œããããšã¯ããããªã圢æ ã«ãããŠãçŠæ¢ããã REF-2
NCCN® è «çåŠå®è·µã¬ã€ãã©ã€ã³
2007 幎第 1 ç ä¹³çã®ã¹ã¯ãªãŒãã³ã°ãšèšºæ
æšå¥šæç®:
Bevers TB. Breast self-examination: An optional screening modality in National Comprehensive Cancer Network breast cancer screening guidelines. Breast Dis 1998;9:230-231.
Cady B, Steele GD, Morrow M et al. Evaluation of common breast problems: Guidance for primary care givers. CA Cancer J Clin 1998;48:49-63.
Cardenosa G, Doudna C, Eklund GW. Ductography of the breast: Technique and findings. AJR Am J Roentgenol 1994;162:1081-1087.
Dawes L, Bowen C, Venta L et al. Ductography for nipple discharge: No replacement for ductal excision. Surgery 1998;124:685-691.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151.
Dupont WD, Parl FF, Hartmann WH et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-1265.
Feig S, D'Orsi C, Hendrick R et al. American College of Radiology guidelines for breast cancer screening. Am J Radiol 1998;171:29-32.
Ligon RE, Stevenson DR, Diner W et al. Breast masses in young women. Am J Surg 1980;140:779-782.
London SJ, Connolly JL, Schnitt SJ et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267:941-944.
O'Malley MS, Fletcher SW. U.S. Preventive Services Task Force: Screening for breast cancer with breast self-examination: A critical review. JAMA 1987;257:2196-2203.
Quality Mammography Standards: Final Rule. 62 Federal Register 55988 (1997).
Salzmann P, Kerlikowske K, Phillips K. Cost effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997;127:955-1036.